SUPPLEMENT TO:

ISSN 00007–1250

THE BRITISH JOURNAL OF PSYCHIATRY

INDEX TO VOLUME 164

JANUARY – JUNE
1994

© The Royal College of Psychiatrists

Index to Volume 164

Compiled by Linda English

PART I — SUBJECTS 3–14

PART II — CONTRIBUTORS 14–22

PART III — BOOK REVIEWS & BJP REVIEW OF BOOKS 22–23

Abbreviations: SP Short Paper; C Correspondence; R of B *BJP Review of Books*; suppl. supplement.

PART I. SUBJECTS

Abnormal Involuntary Movements Scale. Movement disorder in Nigerians with schizophrenia. Robin G. McCreadie and Jude U. Ohaeri 184–189

Adolescence. Cyclic psychosis and the menstrual cycle. A. Ambelas (C) 709

Adoption studies. Finnish adoptive family study of schizophrenia. Pekka Tienari *et al* (suppl. 23) 20–26

Affective disorders
- Cosegregation of major disorder and Darier's disease. Nick Craddock *et al* 355–358
- Effectiveness in psychiatric care. Psychoeducation and outcome for patients and their families. Ira D. Glick *et al* (SP) 104–106
- Recurrent. Lithium prophylaxis. R. Guscott and L. Taylor (*Review Article*) 741–746
- Symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
- *see also* **Bipolar affective disorder, Depression, Dysphoria, Dysthymia, Mania, Melancholia, Schizoaffective disorder** and **Seasonal affective disorder**

Affective style. Disturbed attachment and negative style. Diana Diamond and Jeri A. Doane 770–781

Affect logic. Integrative model of the psyche and its relations to schizophrenia. Luc Ciompi (suppl. 23) 51–55

Africa
- Defeating depression in the developing world: Zimbabwean model. Melanie Abas *et al* (*Editorial*) 293–296
- Perinatal psychiatry. John L. Cox (C) 420
- *see also* **Nigeria**

Afro-Caribbeans. Schizophrenia in the British community. Philip A. Sugarman and David Craufurd 474–480

Age
- Epidemiology of early schizophrenia. H. Häfner *et al* (suppl. 23) 29–38
- Onset of schizophrenia. Gender differences. Stephen V. Faraone *et al* 625–629

Agoraphobia. Panic disorder. Alprazolam and exposure. Metin Başoglu *et al* 647–652, 652–659

A hundred years ago. Henry Rollin
- Hypodermic injections of brain extract in mental diseases. By R. P. Ryan 270
- Kleptomania 709–710
- Neapolitan private asylum. By Fraser Nicolson 855
- Opium Commission 567
- Prevention of suicide 423
- Reports of lunatic asylums for 1892. 134

Akathisia
- Prevalence and asssociated dysphoria in chronic schizophrenia. Simon M. Halstead *et al* 177–183
- Residual psychopathology. John W. Newcomer *et al* (SP) 834–838

Alcohol misuse
- Association between sexual and substance abuse. Joanna Moncrieff (C) 847
- Death during withdrawal. J. D. Chick (C) 853
- Hidden abuse among women. Kaija Seppä *et al* (SP) 544–546
- Schizophrenia. Relationship to symptoms, tardive dyskinesia and illness onset. Peter J. Duke *et al* 630–636

Alprazolam
- Panic disorder with agoraphobia. Metin Başoglu *et al* 647–652
- Panic disorder with agoraphobia. Attribution of improvement to medication predicts relapse. Metin Başoglu *et al* 652–659

Alzheimer's disease
- Genetics. David St Clair (*Editorial*) 153–156
- Lewy body dementia. Raymond Levy (C) 268

Amnesia. Neural network model. Eric Y. H. Chen (C) 125–126

Analyses. Life-table method. Lithium in bipolar illness. Eric D. Peselow *et al* 208–214

Anorexia nervosa. Anorexic siblings. Peter Hall (C) 268–269

Anorgasmia. Fluvoxamine-induced. Successful treatment by cyproheptadine. Steve Arnott and David Nutt (SP) 838–839

Anticipation. Relevance to genetic studies of schizophrenia? Philip Asherson *et al* 619–624

Antipsychotics
- New atypical. R. W. Kerwin (*Editorial*) 141–148
- Use of high-dose medication. C. Thompson (*Consensus Statement*) 448–458. Comment. John M. Kane (*Editorial*) 431–432
- *see also* **Neuroleptics** and individual names

Anxiety disorders
- Anticipatory anxiety. Panic disorder with agoraphobia. Metin Başoglu *et al* 647–652
- Panic disorder. An overlapping or independent entity? A. Okasha *et al* 818–825
- Tourette's syndrome. David L. Pauls *et al* 215–221
- *see also* **Panic disorder** and **Phobias**

Aqueduct stenosis. Schizophrenic psychosis. S. O'Flaithbheartaigh *et al* (SP) 684–686

Assessment. Psychiatric assessment at the magistrates' court. Philip L. A. Joseph (*Editorial*) 722–724

Asylums *see* **Hospitals**

Attachment
An attachment school of psychotherapy. Myrna M. Weissman (C) 420–421
Disturbed attachment and negative affective style. Diana Diamond and Jeri A. Doane 770–781
Theory. Simon R. Wilkinson (C) 129–130. C. E. Rowe (C) 130–131
Attributional Style Questionnaire. Defensive function of persecutory delusions. Helen M. Lyon *et al* 637–646
Attributions
Defensive function of persecutory delusions. Helen M. Lyon *et al* 637–646
Panic disorder. Attribution of improvement to medication predicts relapse. Metin Başoglu *et al* 652–659
Australia antigen (HBsAg). Prevalence in institutionalised patients with psychosis. S. Chaudhury *et al* (SP) 542–543

Barnes Akathisia Scale. Movement disorder in Nigerians with schizophrenia. Robin G. McCreadie and Jude U. Ohaeri 184–189
Basal ganglia. D_2 dopamine receptor binding. Schizophrenic patients. L. S. Pilowsky *et al* 16–26
Behavioural family management. Schizophrenia. Eugenia T. Randolph *et al* 501–506
Benzodiazepines. Fatal poisonings. Konrad Michel and Thomas Spuhler (C) 128–129
Bethlem Royal Hospital. Report for 1892. Henry Rollin (*A hundred years ago*) 134
Biperidene. Intravenous. Treatment of catatonia. Michael Franz *et al* (C) 847–848
Bipolar affective disorder
Bipolar affective puerperal psychosis and consanguinity. Nick Craddock *et al* 359–364
Chromosomal aberrations. Nick Craddock and Mike Owen 507–512
Life events and relapse. Fergus O'Croinin *et al* (C) 417
Lithium prophylaxis. Eric D. Peselow *et al* 208–214
Recurrence of mania after lithium withdrawal. Guy M. Goodwin (*Editorial*) 149–152
Bosnia. Psychiatric consequences of war. L. Stephen O'Brien (*Editorial*) 443–447
Boston Naming Test. Is there cognitive decline in schizophrenia? Thomas M. Hyde *et al* 494–500
Brain
Aqueduct stenosis and schizophrenic psychosis. S. O'Flaithbheartaigh *et al* (SP) 684–686
Biological factors in schizophrenia. E. K. G. Syvälahti (suppl. 23) 9–14
Functional anatomy of obsessive–compulsive phenomena. P. K. McGuire *et al* 459–468
Hypodermic injections of extract in mental diseases. By R. P. Ryan. Henry Rollin (*A hundred years ago*) 270
Mind and behaviour. John Gunn (C) 416. Andrew S. Horne (C) 416–417. Andrew H. Reid and Helen E. Kirk (C) 708–709
Self-inflicted intracranial injury. B. K. Puri *et al* (SP) 841–842
Thalamo-frontal psychosis. Anoop Ranjan Varma (C) 124–125
see also **Basal ganglia, Computerised tomography, Electroencephalography, Lewy bodies, Magnetic resonance imaging, Neurotransmitters, Positron emission tomography, Single photon emission computerised tomography** and **Stroke**
Brain-washing. *Battle for the Mind – A Physiology of Conversion and Brain-Washing*. William Sargant (John Birtchnell) (*Books reconsidered*) 273–275
Brief Psychiatric Rating Scale
Akathisia and residual psychopathology. John W. Newcomer *et al* (SP) 834–838
Behavioural family management in schizophrenia. Eugenia T. Randolph *et al* 501–506
Britain
Schizophrenia in the Afro-Caribbean community. Philip A. Sugarman and David Craufurd 474–480
see also **Edinburgh** and **London**
British Journal of Psychiatry
Achieving excellence. Greg Wilkinson (*Editorial*) 1
Points of style. David Owens *et al* (C) 697. Editor's reply 697
Brixton Prison. Psychotic men remanded in custody. Graham Robertson *et al* 55–61
Broadbent, D. E. *Perception and Communication*. Michael W. Eysenck (*Books reconsidered*) 711–712
Bulimia nervosa. Follow-up of patients. Sunny Collings and Michael King 80–87
Buspirone. 5-HT_{1A} receptor sensitivity in major depression. Neuroendocrine study. P. J. Cowen *et al* 372–379

Cannabis
Consumption as a prognostic factor in schizophrenia. M. J. Martinez-Arevalo *et al* (SP) 679–681
Psychosis. James Lindesay (C) 566
Toxic psychosis while on disulfiram. James Mackie and Donald Clark (C) 421
Capgras' syndrome. Three cases. Sheila J. Frazer and Jeremy M. Roberts (SP) 557–559
Carbamazepine. Neuroleptic malignant syndrome. Therese van Amelsvoort (C) 269–270
Catatonia. Treatment with intravenous biperidene. Michael Franz *et al* (C) 847–848
Cerebral infarction. Effect of lithium in patients with SLE, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111
Chartres study. I. Prevalence of psychiatric disorders among school-aged children. Eric Fombonne 69–79
Child Behavior Checklist. The Chartres study. Eric Fombonne 69–79
Childbirth *see* **Obstetric complications, Pregnancy** and **Puerperium**
Childhood
Abuse in first-episode psychosis. Shelly F. Greenfield *et al* (SP) 831–834
Chartres study: I. Prevalence of psychiatric disorders among school-aged children. Eric Fombonne 69–79
Chronic physical illness and emotional disorder. M. E. Garralda (*Editorial*) 8–10
Psychiatric presentation of Crohn's disease. H. Rickards *et al* (SP) 256–261
Sexual abuse and mental health. Johann F. Kinzl and Wilfried Biebl (C) 707
Children Global Assessment Scale. The Chartres study. Eric Fombonne 69–79
Chlorpromazine. Combined with ECT in mania. Sudip Sikdar *et al* 806–810
Cholesterol. Low serum concentrations and suicide attempts. Noriyoshi Takei *et al* (C) 702–703
Chromosomes. Aberrations and bipolar affective disorder. Nick Craddock and Mike Owen 507–512
Chronic tic disorder. OCD with and without a chronic tic disorder. Jacob C. Holzer *et al* 469–473

City residence. Schizophrenia. Hugh Freeman (suppl. 23) 39–50
Classification
Heterogeneity of depression. Kathleen Ries Merikangas *et al* 342–348
ICD–10: a neuropsychiatrist's nightmare? Shôn Lewis (*Editorial*) 157–158
Nosological models in psychiatry. Pierre Pichot (*Lecture*) 232–240
Clozapine
Cognitive impairment. Janet Carter *et al* (C) 132–133
Creatine kinase elevations. Matcheri S. Keshavan *et al* (SP) 118–120
Exacerbation of obsessive–compulsive symptoms. M. J. Eales and A. O. Layeni (SP) 687–688
Induced neutropenia. Dominic Beer *et al* (C) 850
New atypical antipsychotics. R. W. Kerwin (*Editorial*) 141–148
Safety and efficacy? Harold Bourne (C) 267–268
Cocaine
Determining the prevalence of use. Michael Gossop *et al* (SP) 676–679
Patterns of use, route of administration, and severity of dependence. Michael Gossop *et al* 660–664
Cognition
Impairment and clozapine. Janet Carter *et al* (C) 132–133
Impairment. Sleep deprivation as a diagnostic instrument. C. J. Williams *et al* (SP) 554–556
Is there decline in schizophrenia? Thomas M. Hyde *et al* 494–500
Perception and Communication. D. E. Broadbent (Michael W. Eysenck) (*Books reconsidered*) 711–712
Cognitive behaviour therapy. Schizophrenia. David Kingdon *et al* (*Editorial*) 581–587
Cognitive therapy
Comparison of treatments of panic disorder. David M. Clark *et al* 759–769
Omnipotence of voices. An approach to auditory hallucinations. Paul Chadwick and Max Birchwood 190–201
Community care. Treatment need of schizophrenic patients in Finland. Raimo K. R. Salokangas (suppl. 23) 115–120. Discussion. Johan Cullberg (suppl. 23) 121–122
Community psychiatry. Schizophrenia. Intricacy of the ordinary. Tom Sørensen (suppl. 23) 108–114. Discussion. Johan Cullberg (suppl. 23) 121–122
Comprehensive Assessment and Referral Evaluation. Depression among older people. M. R. Blanchard *et al* 396–402
Comprehensive Psychopathological Rating Scale. Postpartum 'highs' and depression. Vivette Glover *et al* 517–521
Computerised tomography (CT). Results during first admission for psychosis. George Gewirtz *et al* 789–795
Consanguinity. Bipolar affective puerperal psychosis. Nick Craddock *et al* 359–364
Conversion, religious. *Battle for the Mind – A Physiology of Conversion and Brain-Washing*. William Sargant (John Birtchnell) (*Books reconsidered*) 273–275
Corticosteroid. Effect of lithium in patients with SLE and cerebral infarction, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111
Costs. Depression. Cost and cost-effectiveness of pharmacological treatment. Bengt Jönsson and Paul E. Bebbington 665–673
Creatine kinase. Elevations with clozapine. Matcheri S. Keshavan *et al* (SP) 118–120
Croatia. Schizophrenia. Brian Cooper and John M. Eagles (*Current Literature*) 97–100
Crohn's disease. Psychiatric presentation. H. Rickards *et al* (SP) 256–261
Cultures
Koro: culture-bound disorder or universal symptom? R. A Adeniran and J. R. Jones (SP) 559–561
Schizophrenia: the DOSMD challenge. Robert B. Edgerton and Alex Cohen 222–231
Cyproheptadine. Treatment of fluvoxamine-induced anorgasmia. Steve Arnott and David Nutt (SP) 838–839
Cytokines. IL-1α and IL-6 concentrations with neuroleptic treatment. Hai-Min Xu *et al* (SP) 251–253

Darier's disease. Familial cosegregation with major affective disorder. Nick Craddock *et al* 355–358
Debt
Deliberate self-harm. Simon J. Taylor (C) 848–849
Deliberate self-poisoning. Simon Hatcher (SP) 111–114
Defeat Depression Campaign. Improving management and knowledge of depression. Marking "Action Week". R. G. Priest (*Editorial*) 285–287
Delusions
Amenability to reasoning. Cognitive behaviour therapy of schizophrenia. David Kingdon *et al* (*Editorial*) 581–587
Delusional gross replacement of inanimate objects. Pura M. Castillo and Carol W. Berman (SP) 693–696
Persecutory. Defensive function. Helen M. Lyon *et al* 637–646
Pregnancy. Albert Michael *et al* (SP) 244–246
Three cases of Capgras' syndrome. Sheila J. Frazer and Jeremy M. Roberts (SP) 557–559
see also **Erotomania**
Dementia
Alzheimer's disease and Lewy body dementia. Raymond Levy (C) 268
Elderly in a rural Korean community. Jonghan Park *et al* 796–801
Dementia Rating Scale. Is there cognitive decline in schizophrenia? Thomas M. Hyde *et al* 494–500
Depression
Aetiology
Glucocorticoids and the genesis of illness. Timothy G. Dinan 365–371. Alexander J. Mitchell (C) 853–854
Social competition hypothesis. John Price *et al* 309–315
Complications
Affective symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
Effect of lithium in patients with SLE and cerebral infarction, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111
Long-term survivors of stroke. Michael Sharpe *et al* 380–386
Panic disorder. An overlapping or independent entity? A.Okasha *et al* 818–825
Social adjustment in panic–agoraphobic patients reconsidered. G. Perugi *et al* 88–93
Tourette's syndrome. David L. Pauls *et al* 215–221
Diagnosis. Sleep deprivation as a diagnostic instrument. C. J. Williams *et al* (SP) 554–556
Epidemiology
Geomagnetic storms: association with incidence. Ronald W. Kay 403–409
Older people in inner London, and contact with primary care. M. R. Blanchard *et al* 396–402

Genetics. Tourette's syndrome. Evidence against a relationship. David L. Pauls *et al* 215–221
Models
Defining melancholia: properties of a refined sign-based measure. Gordon Parker *et al* 316–326
Glucocorticoids and the genesis of illness. Psychobiological model. Timothy G. Dinan 365–371
Heterogeneity. Classification of subtypes by longitudinal course. Kathleen Ries Merikangas *et al* 342–348
Outcome
Long-term: future imperfect. P. G. Surtees and C. Barkley 327–341
In psychiatric settings. Marco Piccinelli and Greg Wilkinson (*Review Article*) 297–304. Alan Lee and Gordon Parker (*Peer Review*) 305–308
Physiopathology. 5-HT_{1A} receptor sensitivity in major depression. P. J. Cowen *et al* 372–379
Psychology. Personality traits during depression and after clinical recovery. Eric D. Peselow *et al* 349–354
Therapy
Antidepressant effects of ECT. B. N. Gangadhar and N. Janakiramaiah (C) 123–124
Cost and cost-effectiveness of pharmacological treatment. Bengt Jönsson and Paul E. Bebbington 665–673
Defeating depression in the developing world: Zimbabwean model. Melanie Abas *et al* (*Editorial*) 293–296
Delay in the antidepressant effect of ECT. Colin R. Rodger *et al* (SP) 106–109
Edinburgh primary care study. J. Scott *et al* (*Current Literature*) 410–415
Effect of lithium in patients with SLE and cerebral infarction, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111
Nefazodone and imipramine. Karl Rickels *et al* 802–805
Onset of the antidepressant effect of ECT. Charles H. Kellner *et al* (C) 565–566
Semi-structured scale sensitive to change with treatment for use in the elderly. A. V. Ravindran *et al* 522–527
see also **Defeat Depression Campaign** and **Puerperium**
Depression Outcome Scale. Long-term outcome of depression. P. G. Surtees and C. Barkley 327–341
Developing countries
Culture and schizophrenia: the DOSMD challenge. Robert B. Edgerton and Alex Cohen 222–231
Defeating depression: Zimbabwean model. Melanie Abas *et al* (*Editorial*) 293–296
Diagnoses
Declining incidence of schizophrenia. Fiona Clunie and John B. Stewart (C) 564. John R. Geddes *et al* (*Authors' reply*) (C) 564–565
Delay and increased morbidity. Psychiatric presentation of Crohn's disease. H. Rickards *et al* (SP) 256–261
Sleep deprivation as a diagnostic instrument. C. J. Williams *et al* (SP) 554–556
DIDMOAD (Wolfram) syndrome. M. Kellner *et al* (C) 132
Diogenes syndrome. By proxy. Denis O'Mahony and J. Grimley Evans (C) 705–706
Disulfiram. Cannabis toxic psychosis. James Mackie and Donald Clark (C) 421
Dopamine
Central D_2 receptors and negative symptoms of schizophrenia. J. L. Martinot *et al* 27–34
D_2 receptor binding in the basal ganglia of schizophrenic patients. L. S. Pilowsky *et al* 16–26
Down's syndrome
Prevalence and associated features of epilepsy in adults. R. W. McVicker *et al* 528–532
Rarity of mania. Robert H. Howland (C) 422
Drug misuse
Association between sexual and substance abuse. Joanna Moncrieff (C) 847
Declining incidence of schizophrenia. Fiona Clunie and John B. Stewart (C) 564. John R. Geddes *et al* (*Authors' reply*) (C) 564–565
Opium Commission. Henry Rollin (*A hundred years ago*) 567
Risk of HIV for women who inject. Sally Porter *et al* (C) 849
Sex differences in patterns of drug taking behaviour. Michael Gossop *et al* (SP) 101–104
see also **Alcohol misuse, Cannabis** and **Cocaine**
Drugs
Cost of depression and cost-effectiveness of pharmacological treatment. Bengt Jönsson and Paul E. Bebbington 665–673
Maintenance therapy for schizophreniform disorder. Philip Stokes *et al* (C) 565
see also **Alprazolam, Antipsychotics, Benzodiazepines, Biperidene, Buspirone, Cannabis, Carbamazepine, Chlorpromazine, Clozapine, Cocaine, Corticosteroid, Cyproheptadine, Disulfiram, Fluoxetine, Fluvoxamine, Imipramine, Inositol, Lithium, Nasal decongestant, Nefazodone, Neuroleptics, Opium, Paroxetine, Selective serotonin re-uptake inhibitors** and **Tricyclics**
Dyschronia. A patient with Tourette's syndrome. Iain McGilchrist *et al* (SP) 261–263
Dysphagia. Neuroleptic malignant syndrome. J. Shamash *et al* (C) 849–850
Dysphoria
Akathisia and residual psychopathology. John W. Newcomer *et al* (SP) 834–838
Associated with akathisia. Chronic schizophrenia. Simon M. Halstead *et al* 177–183
Dysthymia. Mental handicap. J. Jancar and I. J. Gunaratne (SP) 691–693
Dystonia. Acute reactions and psychotic phenomena. A. Thornton and P. J. McKenna (SP) 115–118

Edinburgh. Primary care depression study. J. Scott *et al* (*Current Literature*) 410–415
Edinburgh Postnatal Depression Scale. Postnatal psychiatric morbidity. C. G. Ballard *et al* 782–788
Elderly
Dementia in a rural Korean community. Jonghan Park *et al* 796–801
Depression in inner London, and contact with primary care. M. R. Blanchard *et al* 396–402
Diogenes syndrome by proxy. Denis O'Mahony and J. Grimley Evans (C) 705–706
Semi-structured depression scale. A. V. Ravindran *et al* 522–527
Unipolar mania reconsidered. Kenneth I. Shulman and Mauricio Tohen (SP) 547–549
Electroconvulsive therapy (ECT)
Administrative problems limiting therapy. Max Fink (C) 850–851
Antidepressant effects. B. N. Gangadhar and N. Janakiramaiah (C) 123–124
Combined with chlorpromazine in mania. Sudip Sikdar *et al* 806–810

Delay in the antidepressant effect. Colin R. Rodger *et al* (SP) 106–109
Onset of the antidepressant effect. Charles H. Kellner *et al* (C) 565–566
Tricyclic-induced seizures and absent response. S. Curran (C) 421
Electroencephalography (EEG). Abnormalities in monozygotic twins with Tourette's syndrome. Thomas M. Hyde *et al* 811–817
Emotion. Physiological effects: assessment via hypnosis. T. D. Rogers and David Waxman (*Current Literature*) 241–243
Emotional disorders. Chronic physical illness in childhood. M. E. Garralda (*Editorial*) 8–10
Environmental hypersensitivity. SAD and somatisation. Matthew Hotopf (SP) 246–248
Epilepsy. Adults with Down's syndrome. R. W. McVicker *et al* 528–532
Erotomania. Homosexual. HIV infection. Neil Boast and Jeremy Coid (SP) 842–846
Ethnicity. Nomenclature. Roland Littlewood and Sushrut Jadhav (C) 419
Ethnic minorities
Psychiatric morbidity and compulsory admission. Bernard Ineichen (C) 267. Christopher S. Thomas *et al* (*Authors' reply*) (C) 267
Schizophrenia in the Afro-Caribbean community. Philip A. Sugarman and David Craufurd 474–480
Euthanasia. Variations on the theme. Tony Whitehead (C) 131. M. M. Salzmann (C) 131
Exposure. Panic disorder with agoraphobia. Metin Başoglu *et al* 647–652, 652–659
Eye-movement desensitisation. Symptom change in PTSD. K. Vaughan *et al* 533–541

Families
Disturbed attachment and negative affective style. Diana Diamond and Jeri A. Doane 770–781
Familial cosegregation of affective disorder and Darier's disease. Nick Craddock *et al* 355–358
Finnish adoptive family study of schizophrenia. Pekka Tienari *et al* (suppl. 23) 20–26. Comment. Johannes Lehtonen (suppl. 23) 27–28
Grief. David W. Kissane and Sidney Bloch (*Review Article*) 728–740
Origins of schizophrenia. Individual–psychological and interactional concepts. Yrjö O. Alanen (suppl. 23) 56–61
Parental bonding. John Birtchnell (C) 125
Psychoeducation and outcome for patients with major affective disorder and their families. Ira D. Glick *et al* (SP) 104–106
Family history method
Heritability of schizophrenia. Nigeria. O. Gureje *et al* 481–486
Schizophrenia in the Afro-Caribbean community. Philip A. Sugarman and David Craufurd 474–480
Family therapy
Behavioural family management in schizophrenia. Eugenia T. Randolph *et al* 501–506
Need-adapted treatment of schizophrenia. Klaus Lehtinen (suppl. 23) 89–96
Working with the families of schizophrenic patients. Julian Leff (suppl. 23) 71–76
Fathers. Postnatal psychiatric morbidity. C. G. Ballard *et al* 782–788
Finland
Adoptive family study of schizophrenia. Pekka Tienari *et al* (suppl. 23) 20–26. Comment. Johannes Lehtonen (suppl. 23) 27–28
Community care and treatment need of schizophrenic patients. Raimo K. R. Salokangas (suppl. 23) 115–120. Discussion. Johan Cullberg (suppl. 23) 121–122
Fluoxetine. Beneficial sexual side-effects. Parsley Power-Smith (SP) 249–250
Fluvoxamine
Emergence of symptoms of Tourette's syndrome during treatment of OCD. S. Fennig *et al* (SP) 839–841
Prescription-event monitoring of patients. J. Guy Edwards *et al* 387–395. J. J. Ashford (C) 852–853
Treatment of induced anorgasmia by cyproheptadine. Steve Arnott and David Nutt (SP) 838–839
Folnegović, Z. and Folnegović-Šmalc, V. Schizophrenia in Croatia. Brian Cooper and John M. Eagles (*Current Literature*) 97–100
France. Chartres study: I. Prevalence of psychiatric disorders among school-aged children. Eric Fombonne 69–79

Gender differences
Age at onset of schizophrenia. Stephen V. Faraone *et al* 625–629
Decline in the rate of schizophrenia. John L. Waddington and Hanafy A. Youssef 171–176
Epidemiology of early schizophrenia. H. Häfner *et al* (suppl. 23) 29–38
Patterns of drug taking behaviour. Michael Gossop *et al* (SP) 101–104
General practice *see* **Primary care**
Genetics
All that tics may not be Tourette's. Valsamma Eapen and Mary M. Robertson (C) 708
Alzheimer's disease. David St Clair (*Editorial*) 153–156
Bipolar affective puerperal psychosis and consanguinity. Nick Craddock *et al* 359–364
Chromosomal aberrations and bipolar affective disorder. Nick Craddock and Mike Owen 507–512
Cosegregation of affective disorder and Darier's disease. Nick Craddock *et al* 355–358
Estimates of risks in relatives of psychotic probands. Nick Craddock and Luis Giuffra (C) 706–707
Linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal region. Timothy J. Crow *et al* 159–164
Mental retardation. Anita Thapar *et al* 747–758
Schizophrenia *see* **Schizophrenia,** *Genetics*
Tourette's syndrome and psychiatric disorders. David L. Pauls *et al* 215–221
Geomagnetic storms. Incidence of depression. Ronald W. Kay 403–409
Geriatric Mental State
GMS-AGECAT. Depression among older people. M. R. Blanchard *et al* 396–402
GMS-Depression Scale. Semi-structured scale for the elderly. A. V. Ravindran *et al* 522–527
Glucocorticoids. Genesis of depressive illness. Timothy G. Dinan 365–371. Alexander J. Mitchell (C) 853–854
Grief. Family grief. David W. Kissane and Sidney Bloch (*Review Article*) 728–740

Hallucinations
Amenability to reasoning. Cogntive behaviour therapy of schizophrenia. David Kingdon *et al* (*Editorial*) 581–587
Auditory. Omnipotence of voices: cognitive approach. Paul Chadwick and Max Birchwood 190–201

Hepatitis B virus infection. Australia antigen in institutionalised patients with psychosis. S. Chaudhury *et al* (SP) 542–543
Highs scale. Postpartum 'highs' and depression. Vivette Glover *et al* 517–521
HIV infection
Homosexual erotomania. Neil Boast and Jeremy Coid (SP) 842–846
Risk for women who inject drugs. Sally Porter *et al* (C) 849
Homosexuality
Erotomania and HIV infection.Neil Boast and Jeremy Coid (SP) 842–846
Homosexual orientation. Search for a biological basis. John Bancroft (*Editorial*) 437–440
Hormones. Biological and hormonal aspects of postpartum depressed mood. Brian Harris (*Editorial*) 288–292
see also **Neuroendocrine system**
Hospitals
Geomagnetic storms and incidence of depression as measured by admissions. Ronald W. Kay 403–409
HBsAg in institutionalised patients with psychosis. S. Chaudhury *et al* (SP) 542–543
Neapolitan private asylum. By Fraser Nicolson. Henry Rollin (*A hundred years ago*) 855
Psychiatric morbidity and compulsory admission. Bernard Ineichen (C) 267. Christopher S. Thomas *et al* (*Authors' reply*) (C) 267
Reports of lunatic asylums for 1892. Henry Rollin (*A hundred years ago*) 134
Shared image guiding treatment. Schizophrenia. Jukka Aaltonen and Viljo Räkköläinen (suppl. 23) 97–102
Violence in psychiatric intensive care. Zuzana Walker and Ruth Seifert (SP) 826–828
5-Hydroxytryptamine *see* **Serotonin**
Hypnosis. Physiological effects of emotion. Assessment. T. D. Rogers and David Waxman (*Current Literature*) 241–243
Hypomania. Postpartum 'highs' and depression. Vivette Glover *et al* 517–521
Hypothalamic–pituitary–adrenal axis (HPA). Glucocorticoids and genesis of depressive illness. Timothy G. Dinan 365–371. Alexander J. Mitchell (C) 853–854

ICD–10. A neuropsychiatrist's nightmare? Shôn Lewis (*Editorial*) 157–158
Imipramine
A comparison of treatments of panic disorder. David M. Clark *et al* 759–769
Major depression. Karl Rickels *et al* 802–805
What price depression? Bengt Jönsson and Paul E. Bebbington 665–673
Imprinting. Relevance to genetic studies of schizophrenia? Philip Asherson *et al* 619–624
Influenza
Maternal influenza and schizophrenia. J.-P. C. J. Selten and J. P. J. Slaets (SP) 674–676
Prenatal exposure as a cause of schizophrenia. T. J. Crow (*Editorial*) 588–592
Inositol. Levels and lithium dosage. Nimrod Grisaru and R. H. Belmaker (C) 133–134
Interviews
Interview for the Retrospective Assessment of the Onset of Schizophrenia. Epidemiology. H. Häfner *et al* (suppl. 23) 29–38
Structured Interview for DSM–III Personality Disorder. Personality in depression and recovery. Eric D. Peselow *et al* 349–354
Ireland. Gender-specific decline in the rate of schizophrenia. John L. Waddington and Hanafy A. Youssef 171–176
Irritable bowel syndrome. Physiological effects of emotion. T. D. Rogers and David Waxman (*Current Literature*) 241–243

Jealousy. Community study. Paul E. Mullen and J. Martin 35–43

Keratosis. Cosegregation of affective disorder and Darier's disease. Nick Craddock *et al* 355–358
Kleptomania. Henry Rollin (*A hundred years ago*) 709–710
Korea
Dementia among the elderly in a rural community. Jonghan Park *et al* 796–801
Month of birth and schizophrenia. Chul-Eung Kim *et al* (SP) 829–831
Koro. Culture-bound disorder or universal symptom? R. A. Adeniran and J. R. Jones (SP) 559–561

Learning disability. Psychiatry. Andrew H. Reid 613–618
see also **Mental retardation**
Lewy bodies. Dementia and Alzheimer's disease. Raymond Levy (C) 268
Life events. Relapse in bipolar disorder. Fergus O'Croinin *et al* (C) 417
Life-table method. Lithium in bipolar illness. Eric D. Peselow *et al* 208–214
Linkage studies
Cosegregation of affective disorder and Darier's disease. Nick Craddock *et al* 355–358
Pseudoautosomal linkage of schizophrenia. Timothy J. Crow *et al* 159–164
Lithium
Antidepressant effect in patients with SLE and cerebral infarction, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111
Dosage and inositol levels. Nimrod Grisaru and R. H. Belmaker (C) 133–134
Is there a withdrawal syndrome? S. Thalayasingam *et al* (C) 417–418. Neil Hunt (C) 418–419
Neurotoxicity at subtherapeutic serum levels. Richard Prettyman (C) 123
Prophylaxis of bipolar illness: combination treatment. Eric D. Peselow *et al* 208–214
Prophylaxis in recurrent affective illness. R. Guscott and L. Taylor (*Review Article*) 741–746
Recurrence of mania after withdrawal. Guy M. Goodwin (*Editorial*) 149–152
London
Community drug team. Sex differences in patterns of drug taking behaviour. Michael Gossop *et al* (SP) 101–104
Depression among older people in inner London. M. R. Blanchard *et al* 396–402
see also **Brixton prison** and **South Westminster**

Magistrates' courts. Psychiatric assessment. Philip L. A. Joseph (*Editorial*) 722–724
Magnetic resonance imaging. Functional MRI. Anthony David *et al* (*Editorial*) 2–7
Malignant alienation. Darryl Watts and Gethin Morgan (*Editorial*) 11–15. D. R. Davies (C) 697–698. H. G. Morgan and D. Watts (*Authors' reply*) (C) 698

Mania
Combined chlorpromazine and ECT. Sudip Sikdar *et al* 806–810
Induction with SSRIs and tricyclics. Malcolm Peet (SP) 549–550
Rarity in Down's syndrome. Robert H. Howland (C) 422
Recurrence after lithium withdrawal. Guy M. Goodwin (*Editorial*) 149–152
Unipolar reconsidered. Kenneth I. Shulman and Mauricio Tohen (SP) 547–549
see also **Hypomania**
Manipulation. Managing the manipulative therapist. Chris Taylor (C) 698–699
Medico-legal issues
Brain, mind and behaviour. John Gunn (C) 416. Andrew S. Horne (C) 416–417. Andrew H. Reid and Helen E. Kirk (C) 708–709
see also **Euthanasia, Magistrates' courts** and **Prisons**
Melancholia. Definition. Gordon Parker *et al* 316–326
Memory. Verbal fluency and semantic memory in schizophrenia. Eric Y. H. Chen (C) 704
Menopause. Affective symptoms at a clinic. Alistair G. Hay *et al* 513–516
Menstruation. Cyclic psychosis and adolescence. A. Ambelas (C) 709
Mental health. Childhood sexual abuse. Johann F. Kinzl and Wilfried Biebl (C) 707
Mental health care
Effectiveness. Psychoeducation and major affective disorder. Ira D. Glick *et al* (SP) 104–106
A register of randomised controlled trials. Clive Adams and Michael Gelder (*Editorial*) 433–436
Mental Health Foundation. A booklet reviewed. H. G. Morgan (*Editorial*) 725–727
Mental retardation
Assaultiveness among institutionalised adults. Olav M. Linaker 62–68
Dysthymia. J. Jancar and I. J. Gunaratne (SP) 691–693
Genetics. Anita Thapar *et al* 747–758
Psychiatry. Andrew H. Reid 613–618
Mind
Battle for the Mind – A Physiology of Conversion and Brain-Washing. William Sargant (John Birtchnell) (*Books reconsidered*) 273–275
Brain, mind and behaviour. John Gunn (C) 416. Andrew S. Horne (C) 416–417. Andrew H. Reid and Helen E. Kirk (C) 708–709
Mini-Mental State Examination. Is there cognitive decline in schizophrenia? Thomas M. Hyde *et al* 495–500
Montgomery–Asberg Depression Rating Scale. Affective symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
Morbidity
Psychiatric morbidity and compulsory admission. Bernard Ineichen (C) 267. Christopher S. Thomas *et al* (*Authors' reply*) (C) 267
Psychiatric presentation of Crohn's disease. Diagnostic delay and increased morbidity. H. Rickards *et al* (SP) 256–261
Social phobics. Richard Duffett and Martin Laker (C) 419
Mortality. Death during alcohol withdrawal. J. D. Chick (C) 853
see also **Suicide**
Movement disorders. Nigerians with schizophrenia. Robin G. McCreadie and Jude U. Ohaeri 184–189
see also **Akathisia, Dystonia, Neuroleptic malignant syndrome** and **Tardive dyskinesia**
Multiple personality disorder. August Piper Jr (*Review Article*) 600–612

Naples. A private asylum. By Fraser Nicolson. Henry Rollin (*A hundred years ago*) 855
Nasal decongestant. Psychiatric disturbance. K. A. Wood (C) 566–567
Nefazodone. Major depression. Karl Rickels *et al* 802–805
Neural network model. Amnesia. Eric Y. H. Chen (C) 125–126
Neuroendocrine system
Glucocorticoids and the genesis of depressive illness. Timothy G. Dinan 365–371. Alexander J. Mitchell (C) 853–854
5-HT_{1A} receptor sensitivity in major depression. A study with buspirone. P. J. Cowen *et al* 372–379
Neuroleptic malignant syndrome
Administrative problems limiting ECT. Max Fink (C) 850–851
Carbamazepine. Therese van Amelsvoort (C) 269–270
Cautionary tale and surprising outcome. Gavin Cape (SP) 120–122
Dysphagia. J. Shamash *et al* (C) 849–850
Recurrent sinus arrest. A. K. Parry *et al* (SP) 689–691
Neuroleptics
Acute dystonic reactions and psychotic phenomena. A. Thornton and P. J. McKenna (SP) 115–118
Akathisia and residual psychopathology: by-product of neuroleptic induced dysphoria. John W. Newcomer *et al* (SP) 834–838
High-dose. Clinical use. Steven R. Hirsch and Thomas R. E. Barnes (*Comment*) 94–96
IL-1α and IL-6 concentrations with treatment for schizophrenia. Hai-Min Xu *et al* (SP) 251–253
Treatment of patients with schizophrenia. Frits-Axel Wiesel (suppl. 23) 65–70
see also **Antipsychotics** and individual names
Neuropsychiatry. ICD–10: a nightmare? Shôn Lewis (*Editorial*) 157–158
Neurotoxicity. Lithium at subtherapeutic serum levels. Richard Prettyman (C) 123
Neurotransmitters. Functional role of monoaminergic neurotransmission. R. J. Dolan and P. M. Grasby (*Editorial*) 575–580
see also **Dopamine** and **Serotonin**
Neutropenia. Clozapine-induced. Dominic Beer *et al* (C) 850
New Zealand. Tourette's syndrome. Mary M. Robertson *et al* (SP) 263–266
Nigeria
Heritability of schizophrenia. Family history investigation. O. Gureje *et al* 481–486
Movement disorder in schizophrenic patients. Robin G. McCreadie and Jude U. Ohaeri 184–189
Perinatal psychiatry. John L. Cox (C) 420
NIPS project. Patient's own contributions to psychotherapy in schizophrenia. Sidsel Gilbert and Endre Ugelstad (suppl. 23) 84–88

Obsessive–compulsive disorder (OCD)
Exacerbation of symptoms associated with clozapine. M. J. Eales and A. O. Layeni (SP) 687–688
Functional anatomy of phenomena. P. K. McGuire *et al* 459–468
Symptoms of Tourette's syndrome during fluvoxamine treatment. S. Fennig *et al* (SP) 839–841
With and without a chronic tic disorder. Jacob C. Holzer *et al* 469–473

Obstetric complications. Schizophrenia. Flavia Günther-Genta *et al* 165–170
Opium. The Opium Commission. Henry Rollin (*A hundred years ago*) 567
'Organic' mental disorders. ICD–10: a neuropsychiatrist's nightmare? Shôn Lewis (*Editorial*) 157–158

Pain
Objective evaluation of perception in schizophrenia. R. Guieu *et al* (SP) 253–255
SAD. Brian O' Shea (C) 421–422
Panic disorder
A comparison of treatments. David M. Clark *et al* 759–769
An overlapping or independent entity? A. Okasha *et al* 818–825
Social adjustment in panic–agoraphobic patients. G. Perugi *et al* 88–93
Suicidal behaviour. Louis Appleby (*Editorial*) 719–721
Tourette's syndrome. David L. Pauls *et al* 215–221
With agoraphobia. Alprazolam and exposure. Metin Başoglu *et al* 647–652, 652–659
Paraphrenia. Late-onset schizophrenia v. late paraphrenia. Raymond Levy and Osvaldo P. Almeida (C) 127–128
Parental bonding. John Birtchnell (C) 125
Paroxetine
SSRIs to treat sexual dysfunction. Siobhan MacHale and André L. Phanjoo (C) 854
Treatment of night terrors and somnambulism. A. R. Lillywhite *et al* (SP) 551–554
What price depression? Bengt Jönsson and Paul E. Bebbington 665–673
Patients
Contributions to psychotherapy in schizophrenic disorders. Sidsel Gilbert and Endre Ugelstad (suppl. 23) 84–88
Malignant alienation. Darryl Watts and Gethin Morgan (*Editorial*) 11–15. D. R. Davies (C) 697–698. H. G. Morgan and D. Watts (*Authors' reply*) (C) 698
Managing the manipulative therapist. Chris Taylor (C) 698–699
Perinatal psychiatry. Africa. John L. Cox (C) 420
Personality
Premorbid in first-onset psychosis. Tim Dalkin *et al* 202–207
Traits in depression and recovery. Eric D. Peselow *et al* 349–354
Personality disorders *see* **Multiple personality disorder**
Phobias. Tourette's syndrome. David L. Pauls *et al* 215–221
see also **Agoraphobia** and **Social phobia**
Physical illness. Chronic illness and emotional disorder in childhood. M. E. Garralda (*Editorial*) 8–10
Positive and Negative Syndrome Scale. Movement disorder in Nigerians with schizophrenia. Robin G. McCreadie and Jude U. Ohaeri 184–189
Positron emission tomography (PET). Functional anatomy of obsessive–compulsive phenomena. P. K. McGuire *et al* 459–468
Post-traumatic stress disorder (PTSD)
Eye-movement desensitisation. K. Vaughan *et al* 533–541
Severity and the stressor criterion. Michael A. Simpson (C) 704–705
Pragmatic Inference Task. Defensive function of persecutory delusions. Helen M. Lyon *et al* 637–646
Pregnancy. Delusions. Albert Michael *et al* (SP) 244–246
Prenatal factors. Pathogenesis of schizophrenia. Matti O. Huttunen *et al* (suppl. 23) 15–19
see also **Influenza**
Prescription-event monitoring. Patients treated with fluvoxamine. J. Guy Edwards *et al* 387–395. J. J. Ashford (C) 852–853
Primary care
Depression among older people in inner London. Contact. M. R. Blanchard *et al* 396–402
Edinburgh primary care depression study. J. Scott *et al* (*Current Literature*) 410–415
Somatisation. Scott Weich (C) 562. J. W. Paulley (C) 562–563. T. K. J. Craig (*Author's reply*) (C) 563–564
Prisons
Psychiatric disorder in women serving a sentence. Tony Maden *et al* 44–54
Psychotic men remanded in custody to Brixton. Graham Robertson *et al* 55–61
Pseudoautosomal region. Linkage of schizophrenia and schizoaffective disorder. Timothy J. Crow *et al* 159–164
Psychiatric care *see* **Mental health care**
Psychiatric disorders
Chartres study: I. Prevalence among French school-aged children. Eric Fombonne 69–79
Hypodermic injections of brain extract. By R. P. Ryan. Henry Rollin (*A hundred years ago*) 270
ICD–10: a neuropsychiatrist's nightmare? Shôn Lewis (*Editorial*) 157–158
Morbidity among social phobics. Richard Duffett and Martin Laker (C) 419
Morbidity and compulsory admission. Bernard Ineichen (C) 267. Christopher S. Thomas *et al* (*Authors' reply*) (C) 267
Nasal decongestant and psychiatric disturbance. K. A. Wood (C) 566–567
Postnatal morbidity in mothers and fathers. C. G. Ballard *et al* 782–788
Role of monoaminergic neurotransmission. R. J. Dolan and P. M. Grasby (*Editorial*) 575–580
Tourette's syndrome. David L. Pauls *et al* 215–221
Women serving a prison sentence. Tony Maden *et al* 44–54
Psychiatric intensive care unit. Violent incidents. Zuzana Walker and Ruth Seifert (SP) 826–828
Psychiatry
Learning disability. Andrew H. Reid 613–618
Nosological models. Pierre Pichot (*Lecture*) 232–240
War. Martin P. Deahl *et al* (*Editorial*) 441–442
Psychoanalysis
Schizophrenia. Identification with the therapist's functions. Vamik D. Volkan (suppl. 23) 77–82. Comment. Simo Salonen (suppl. 23) 83
Schizophrenia. Integration of the individual–psychological and interactional concepts. Yrjö O. Alanen (suppl. 23) 56–61
Psychodynamic approach. Homosexual erotomania and HIV infection. Neil Boast and Jeremy Coid (SP) 842–846
Psychoeducation. Outcome for patients with major affective disorder and their families. Ira D. Glick *et al* (SP) 104–106
Psychomotor disturbance. Defining melancholia. Gordon Parker *et al* 316–326
Psychopathology. Akathisia and residual psychopathology. John W. Newcomer *et al* (SP) 834–838
Psychoses
Aetiology
Cannabis toxic psychosis while on disulfiram. James Mackie and Donald Clark (C) 421
Cyclic psychosis, menstrual cycle and adolescence. A. Ambelas (C) 709

Homosexual erotomania and HIV infection. Neil Boast and Jeremy Coid (SP) 842–846
Thalamo-frontal psychosis. Anoop Ranjan Varma *et al* (C) 124–125
Complications
Acute dystonic reactions and psychotic phenomena. A. Thornton and P. J. McKenna (SP) 115–118
Cannabis. James Lindesay (C) 566
Childhood abuse in first-episode psychosis. Shelly F. Greenfield *et al* (SP) 831–834
Declining incidence of schizophrenia. Fiona Clunie and John B. Stewart (C) 564. John R. Geddes *et al* (*Authors' reply*) (C) 564–565
HBsAg in institutionalised patients. S. Chaudhury *et al* (SP) 542–543
Genetics
Bipolar affective puerperal psychosis and consanguinity. Nick Craddock *et al* 359–364
Estimates of risks in relatives of probands. Nick Craddock and Luis A. Giuffra (C) 706–707
Physiopathology. CT during first admission. George Gewirtz *et al* 789–795
Prognosis. Prodromal symptoms in schizophrenia. Ashok K. Malla and Ross M. G. Norman 487–493
Psychology. Premorbid personality in first-onset psychosis. Tim Dalkin *et al* 202–207
Therapy. Men remanded in custody to Brixton Prison. Graham Robertson *et al* 55–61
Psychotherapy
An attachment school. Myrna M. Weissman (C) 420–421
Attachment theory. C. E. Rowe (C) 130–131
Managing the manipulative therapist. Chris Taylor (C) 698–699
Schizophrenia. Patients' own contributions. Sidsel Gilbert and Endre Ugelstad (suppl. 23) 84–88
Schizophrenia. Shared image guiding the treatment process. Jukka Aaltonen and Viljo Räkköläinen (suppl. 23) 97–102
see also **Behavioural family management, Cognitive behaviour, Cognitive** and **Family therapy** and **Psychoanalysis**
Puerperium
Biological and hormonal aspects of postpartum depressed mood. Brian Harris (*Editorial*) 288–292
Bipolar affective puerperal psychosis and consanguinity. Nick Craddock *et al* 359–364
Mild hypomania (the highs) in the first week. Association with later depression. Vivette Glover *et al* 517–521
Perinatal psychiatry. John L. Cox (C) 420
Postnatal psychiatric morbidity in mothers and fathers. C. G. Ballard *et al* 782–788

Quality of life. Schizophrenia. Intricacy of the ordinary. Tom Sørensen (suppl. 23) 108–114. Discussion. Johan Cullberg (suppl. 23) 121–122

Randomised controlled trials. Mental health care. A register. Clive Adams and Michael Gelder (*Editorial*) 433–436
Ratio estimation method. Determining the prevalence of cocaine use. Michael Gossop *et al* (SP) 676–679
Relaxation. Comparison of treatments of panic disorder. David M. Clark *et al* 759–769
Remoxipride. New atypical antipsychotics. R. W. Kerwin (*Editorial*) 141–148
Risperidone. New atypical antipsychotics. R. W. Kerwin (*Editorial*) 141–148

Sargant, William. *Battle for the Mind – A Physiology of Conversion and Brain-Washing*. John Birtchnell (*Books reconsidered*) 273–275
Scales
Abnormal Involuntary Movements Scale 184–189
Barnes Akathisia Scale 184–189
Brief Psychiatric Rating Scale 501–506, 834–838
Children Global Assessment Scale 69–79
Comprehensive Psychopathological Rating Scale 517–521
Dementia Rating Scale 494–500
Depression Outcome Scale 327–341
Edinburgh Postnatal Depression Scale 782–788
Highs scale 517–521
Montgomery–Asberg Depression Rating Scale 513–516
Positive and Negative Syndrome Scale 184–189
Semi-structured depression scale for the elderly 522–527
Simpson and Angus Parkinsonism Scale 184–189
Yale–Brown Obsessive–Compulsive Scale 469–473
see also **Attributional Style Questionnaire, Boston Naming Test, Child Behavior Checklist, Comprehensive Assessment and Referral Evaluation, Geriatric Mental State, Interviews, Mini-Mental State Examination, Pragmatic Inference Task** and **Schedule for Affective Disorders and Schizophrenia**
Schedule for Affective Disorders and Schizophrenia. Affective symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
Schizoaffective disorder. Linkage to the pseudoautosomal region. Timothy J. Crow *et al* 159–164
Schizophrenia
Aetiology
Evidence against maternal influenza as a risk factor. J.-P. C. J. Selten and J. P. J. Slaets (SP) 674–676
Obstetric complications. Flavia Günther-Genta *et al* 165–170
Prenatal exposure to influenza as a cause. T. J. Crow (*Editorial*) 588–592
Strength of the genetic effect. Is there room for an environmental influence? Peter McGuffin *et al* (*Hypotheses*) 593–599
Complications
Acute dystonic reactions and psychotic phenomena. A. Thornton and P. J. McKenna (SP) 115–118
Akathisia and dysphoria in an in-patient population. Simon M. Halstead *et al* 177–183
Aqueduct stenosis. S. O'Flaithbheartaigh *et al* (SP) 684–686
Movement disorder in Nigerian patients. Robin G. McCreadie and Jude U. Ohaeri 184–189
South Westminster Survey. Alcohol use. Peter J. Duke *et al* 630–636
Tardive dyskinesia as a risk factor for negative symptoms. Pádraig Wright and Mark Taylor (C) 700–701. Simon J. Taylor (C) 701–702. Peter F. Liddle and Thomas R. E. Barnes (*Authors' reply*) (C) 702
Epidemiology
Afro-Caribbean community. Philip A. Sugarman and David Craufurd 474–480
Croatia. Brian Cooper and John M. Eagles (*Current Literature*) 97–100
Declining incidence. Fiona Clunie and John B. Stewart (C) 564. John R. Geddes *et al* (*Authors' reply*) (C) 564–565

Gender differences in age at onset. Stephen V. Faraone *et al* 625–629
Gender-specific decline in rate in rural Ireland. John L. Waddington and Hanafy A. Youssef 171–176
Month of birth. Korea. Chul-Eung Kim *et al* (SP) 829–831
Genetics
B37 repeats are normal in most patients. D. C. Rubinsztein *et al* (C) 851–852
Estimates of risks in relatives of psychotic probands. Nick Craddock and Luis A. Giuffra (C) 706–707
Finnish adoptive family study. Pekka Tienari *et al* (suppl. 23) 20–26. Comment. Johannes Lehtonen (suppl. 23) 27–28
Heritability. Family history investigation in Nigeria. O. Gureje *et al* 481–486
Imprinting and anticipation. Are they relevant to studies? Philip Asherson *et al* 619–624
Linkage to the pseudoautosomal region. Timothy J. Crow *et al* 159–164
Strength of the genetic effect. Is there room for an environmental influence? Peter McGuffin *et al* (*Hypotheses*) 593–599
Models. Late-onset schizophrenia v. late paraphrenia. Raymond Levy and Osvaldo P. Almeida (C) 127–128
Outcome. Culture: the DOSMD challenge. Robert B. Edgerton and Alex Cohen 222–231
Physiopathology
Central D_2 receptors and negative symptoms. J. L. Martinot *et al* 27–34
D_2 receptor binding in the basal ganglia of antipsychotic-free patients. L. S. Pilowsky *et al* 16–26
Prognosis
Cannabis consumption as a factor. M. J. Martinez-Arevalo *et al* (SP) 679–681
Prodromal symptoms. Ashok K. Malla and Ross M. G. Norman 487–493
Psychology
Is there cognitive decline? Thomas M. Hyde *et al* 494–500
Objective evaluation of pain perception in patients. R. Guieu *et al* (SP) 253–255
Premorbid personality in first-onset psychosis. Tim Dalkin *et al* 202–207
Verbal fluency and semantic memory. Eric Y. H. Chen (C) 704
Therapy
Behavioural family management. Eugenia T. Randolph *et al* 501–506
Cognitive behaviour therapy. David Kingdon *et al* (*Editorial*) 581–587
Exacerbation of obsessive–compulsive symptoms and clozapine. M. J. Eales and A. O. Layeni (SP) 687–688
IL-1α and IL-6 concentrations with neuroleptic treatment. Hai-Min Xu *et al* (SP) 251–253
New atypical antipsychotics. R. W. Kerwin (*Editorial*) 141–148
Treating negative symptoms. Paul Bailey *et al* (C) 699–700. S. J. Duinkerke *et al* (*Authors' reply*) (C) 700
see also **Schizophrenia: integrated approach**
Schizophrenia: integrated approach. Yrjo O. Alanen *et al* (eds) (suppl. 23) 1–122
Introduction. Yrjö O. Alanen 7–8
Theory 9–64
Affect logic. Luc Ciompi 51–55
Biological factors. E. K. J. Syvälahti 9–14
City residence. Hugh Freeman 39–50
Comments on theory. Einar Kringlen 62–64
Epidemiology of early schizophrenia. H. Häfner *et al* 29–38
Finnish adoptive family study. Pekka Tienari *et al* 20–26. From dualism to psychobiological interaction. A comment. Johannes Lehtonen 27–28
Prenatal factors in pathogenesis. Matti O. Huttunen *et al* 15–19
Towards a unified concept. Yrjö O. Alanen 56–61
Treatment 65–122
Community care and treatment need in Finland. Raimo K. R. Salokangas 115–120. Discussion. Johan Cullberg 121–122
Identification with the therapist's functions. Vamik D. Volkan 77–82. Comment. Simo Salonen 83
Intricacy of the ordinary. Tom Sørensen 108–114. Discussion. Johan Cullberg 121–122
Need-adapted treatment: family interventions. Klaus Lehtinen 89–96
Neuroleptic treatment. Frits-Axel Wiesel 65–70
Patients' own contributions to psychotherapy. Sidsel Gilbert and Endre Ugelstad 84–88
The person with schizophrenia as a person. John S. Strauss 103–107
Shared image guiding the treatment process. Jukka Aaltonen and Viljo Räkköläinen 97–102
Working with the families of patients. Julian Leff 71–76
Schizophreniform disorder. Maintenance therapy. Philip Stokes *et al* (C) 565
Scott, A. I. F. and Freeman, C. P. L. Edinburgh primary care depression study. J. Scott *et al* (*Current Literature*) 410–415
Seasonal affective disorder (SAD)
C. Thompson *et al* (C) 127
Environmental hypersensitivity and somatisation. Matthew Hotopf (SP) 246–248
Pain. Brian O'Shea (C) 421–422
Seasonality
Geomagnetic storms and incidence of depression. Ronald W. Kay 403–409
Month of birth and schizophrenia in Korea. Chul-Eung Kim *et al* (SP) 829–831
see also **Seasonal affective disorder**
Seizures
Epilepsy in adults with Down's syndrome. R. W. McVicker *et al* 528–532
Tricyclic-induced. Absent ECT response. S. Curran (C) 421
Selective serotonin re-uptake inhibitors (SSRIs)
Induction of mania. Malcolm Peet (SP) 549–550
To treat sexual dysfunction. Siobhan MacHale and André L. Phanjoo (C) 854
see also individual names
Self-harm
Debt and deliberate self-harm. Simon J. Taylor (C) 848–849
Debt and deliberate self-poisoning. Simon Hatcher (SP) 111–114
Intracranial injury. B. K. Puri *et al* (SP) 841–842
see also **Suicide**
Serotonin. 5-HT_{1A} receptor sensitivity in major depression. P. J. Cowen *et al* 372–379
Sex differences *see* **Gender differences**
Sexual abuse
Childhood abuse in first-episode psychosis. Shelly F. Greenfield *et al* (SP) 831–834

Childhood. Mental health. Johann F. Kinzl and Wilfried Biebl (C) 707
How abuse has affected me. Stephen H. Shaw (C) 706
Substance abuse. Joanna Moncrieff (C) 847
Sexual disorders *see* **Erotomania** and **Jealousy**
Sexual dysfunction
Beneficial side-effects from fluoxetine. Parsley Power-Smith (SP) 249–250
Treated with SSRIs. Siobhan MacHale and André Phanjoo (C) 854
Treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Steve Arnott and David Nutt (SP) 838–839
Shared image guiding the treatment process (SIGTP). Treatment of schizophrenia. Jukka Aaltonen and Viljo Räkköläinen (suppl. 23) 97–102
Siblings. Anorexic. Peter Hall (C) 268–269
Signs. Defining melancholia: properties of a refined sign-based measure. Gordon Parker *et al* 316–326
Simpson and Angus Parkinsonism Scale. Movement disorder in Nigerians with schizophrenia. Robin G. McCreadie and Jude U. Ohaeri 184–189
Single photon emission computerised tomography (SPECT). D_2 receptor binding in the basal ganglia of schizophrenic patients. L. S. Pilowsky *et al* 16–26
Sinus arrest. Recurrent in association with neuroleptic malignant syndrome. A. K. Parry *et al* (SP) 689–691
Sleep deprivation. As a diagnostic instrument. C. J. Williams *et al* (SP) 554–556
Sleep disorders. Treatment of night terrors and somnambulism with paroxetine. A. R. Lillywhite *et al* (SP) 551–554
Social adjustment. Panic–agoraphobic patients. G. Perugi *et al* 88–93
Social competition. Hypothesis of depression. John Price *et al* 309–315
Social phobia. Morbidity. R. Duffett and Martin Laker (C) 419
Somatisation
General practice. Scott Weich (C) 562. J. W. Paulley (C) 562–563. T. K. J. Craig (*Author's reply*) (C) 563–564
SAD and environmental hypersensitivity. Matthew Hotopf (SP) 246–248
South Westminster. Schizophrenia Survey. Alcohol use. Peter J. Duke *et al* 630–636
Staff
Malignant alienation. Darryl Watts and Gethin Morgan (*Editorial*) 11–15. D. R. Davies (C) 697–698. H. G. Morgan and D. Watts (*Authors' reply*) (C) 698
Managing the manipulative therapist. C. Taylor (C) 698–699
Statistics
Life-table analysis. Lithium prophylaxis of bipolar illness. Eric D. Peselow *et al* 208–214
Ratio estimation method for determining the prevalence of cocaine use. Michael Gossop *et al* (SP) 676–679
Stroke
Depressive disorders in long-term survivors. Michael Sharpe *et al* 380–386
Effect of lithium in patients with SLE and cerebral infarction. Takeshi Terao *et al* (SP) 109–111
Structured Interview for DSM–III Personality Disorder. Personality in depression and recovery. Eric D. Peselow *et al* 349–354
Subjectivity. The person with schizophrenia as a person. John S. Strauss (suppl. 23) 103–107
Suicide
Benzodiazepine fatal poisonings. Konrad Michel and Thomas Spuhler (C) 128–129
Low serum cholesterol and attempts. Noriyoshi Takei *et al* (C) 702–703
Malignant alienation. Darryl Watts and Gethin Morgan (*Editorial*) 11–15. D. R. Davies (C) 697–698. H. G. Morgan and D. Watts (*Authors' reply*) (C) 698
Panic and suicidal behaviour. Louis Appleby (*Editorial*) 719–721
Prevention. H. G. Morgan and K. Hawton (C) 126–127
Prevention. Henry Rollin (*A hundred years ago*) 423
Update 1988. H. G. Morgan (*Reading about*) 271–272
Symptoms
Affective symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
D_2 receptors and negative symptoms of schizophrenia. J. L. Martinot *et al* 27–34
Dissociative. Childhood abuse in first-episode psychosis. Shelly F. Greenfield *et al* (SP) 831–834
Exacerbation of obessive–compulsive symptoms and clozapine. M. J. Eales and A. O. Layeni (SP) 687–688
Eye-movement desensitisation. Symptom change in PTSD. K. Vaughan *et al* 533–541
Koro: culture-bound disorder or universal symptom? R. A. Adeniran and J. R. Jones (SP) 559–561
OCD with and without chronic tic disorder. Jacob C. Holzer *et al* 469–473
Prodromal in schizophrenia. Ashok K. Malla and Ross M. G. Norman 487–493
Schizophrenia and alcohol use. Relationship to symptoms. Peter J. Duke *et al* 630–636
Tardive dyskinesia as a risk factor for negative symptoms. Pádraig Wright and Mark Taylor (C) 700–701. Simon J. Taylor (C) 701–702. Peter F. Liddle and Thomas R. E. Barnes (*Authors' reply*) (C) 702
Tourette's syndrome symptoms during fluvoxamine treatment of OCD. S. Fennig *et al* (SP) 839–841
Treating negative symptoms. Paul Bailey *et al* (C) 699–700. S. J. Duinkerke *et al* (*Authors' reply*) (C) 700
Syndromes. Is there a lithium withdrawal syndrome? S. Thalayasingam *et al* (C) 417–418. Neil Hunt (C) 418–419
see also **Capgras', DIDMOAD, Diogenes, Down's, Irritable bowel, Neuroleptic malignant** and **Tourette's**
Systemic lupus erythematosus (SLE)
ANA negative SLE. Stephen R. J. Moorhead and Alan S. Lee (SP) 682–683
Effect of lithium in patients with SLE and cerebral infarction, treated with corticosteroid. Takeshi Terao *et al* (SP) 109–111

Tardive dyskinesia
As a risk factor for negative symptoms. Pádraig Wright and Mark Taylor (C) 700–701. Simon J. Taylor (C) 701–702. Peter F. Liddle and Thomas R. E. Barnes (*Authors' reply*) (C) 702
Schizophrenia and alcohol use. Peter J. Duke *et al* 630–636
Thalamo-frontal psychosis. Anoop Ranjan Varma *et al* (C) 124–125
Tic disorders
All that tics may not be Tourette's. Valsamma Eapen and Mary M. Robertson (C) 708
OCD with and without chronic tic disorder. Jacob C. Holzer *et al* 469–473
see also **Tourette's syndrome**
Tourette's syndrome
'Dyschronia' in a patient presenting as maternal neglect. Iain McGilchrist *et al* (SP) 261–263

EEG abnormalities in monozygotic twins. Thomas M. Hyde *et al* 811–817
Emergence of symptoms during fluvoxamine treatment of OCD. S. Fennig *et al* (SP) 839–841
Evidence against a genetic relationship with psychiatric disorders. David L. Pauls *et al* 215–221
New Zealand. Mary M. Robertson *et al* (SP) 263–266
Tics. Valsamma Eapen and Mary M. Robertson (C) 708
Tricyclics
Induced seizures and absent ECT response. S. Curran (C) 421
Induction of mania. Malcolm Peet (SP) 549–550
Twins. EEG abnormalities with Tourette's syndrome. Thomas M. Hyde *et al* 811–817

Unipolar mania. Reconsidered. Evidence from an elderly cohort. Kenneth I. Shulman and Mauricio Tohen (SP) 547–549

Verbal fluency. Semantic memory. Schizophrenia. Eric Y. H. Chen (C) 704
Violence
Assaultiveness and mental retardation. Olav M. Linaker 62–68
Incidents in a psychiatric intensive care unit. Zuzana Walker and Ruth Seifert (SP) 826–828

War
Bosnia. Psychiatric consequences. L. Stephen O'Brien (*Editorial*) 443–447
Psychiatry. Martin P. Deahl *et al* (*Editorial*) 441–442
Whorwell, P. J. *et al*. Physiological effects of emotion: assessment via hypnosis. T. D. Rogers and David Waxman (*Current Literature*) 241–243
Women
Affective symptoms at a menopause clinic. Alistair G. Hay *et al* 513–516
Hidden alcohol abuse. Kaija Seppä *et al* (SP) 544–546
Risk of HIV for drug injectors. Sally Porter *et al* (C) 849
Serving a prison sentence. Psychiatric disorder. Tony Maden *et al* 44–54
see also **Gender differences, Menstruation** and **Puerperium**
World Health Organisation: Determinants of Outcome of Severe Mental Disorders study
Culture and schizophrenia: the DOSMD challenge. Robert B. Edgerton and Alex Cohen 222–231
Premorbid personality in psychosis. Tim Dalkin *et al* 202–207

Yale–Brown Obsessive–Compulsive Scale. OCD with and without chronic tic disorder. Jacob C. Holzer *et al* 469–473
Yugoslavia, former. Psychiatry and war. Martin P. Deahl *et al* (*Editorial*) 441–442
see also **Bosnia** and **Croatia**

Zimbabwe. Defeating depression in the developing world: a model. Melanie Abas *et al* (*Editorial*) 293–296

PART II. CONTRIBUTORS

Aaltonen, Jukka and **Räkköläinen, Viljo**. The shared image guiding the treatment process. A precondition for integration of the treatment of schizophrenia (suppl. 23) 97–102
Abas, Melanie *et al*. Defeating depression in the developing world: a Zimbabwean model (*Editorial*) 293–296
Abe, Kazuhiko *see* **Terao, Takeshi** *et al* (SP) 109–111
Adams, Clive and **Gelder, Michael**. The case for establishing a register of randomised controlled trials of mental health care (*Editorial*) 433–436
Adams, Diana *see* **Glover, Vivette** *et al* 517–521
Adeniran, R. A. and **Jones, J. R.** Koro: culture-bound disorder or universal symptom? (SP) 559–561
Aderibigbe, Y. A. *see* **Gureje, O.** *et al* 481–486
Akiskal, H. S. *see* **Perugi, G.** *et al* 88–93
Alanen, Yrjö O. An attempt to integrate the individual–psychological and interactional concepts of the origins of schizophrenia (suppl. 23) 56–61
Alanen, Yrjö O. Introduction (suppl. 23) 7–8
Allen, N. H. P. *see* **Thompson, C.** *et al* (C) 127
Allilaire, J. F. *see* **Martinot, J. L.** *et al* 27–34
Almeida, Osvaldo P. *see* **Levy, Raymond** (C) 127–128
Ambelas, A. Cyclic psychosis, menstrual cycle and adolescence (C) 709
Amelsvoort, Therese van. Neuroleptic malignant syndrome and carbamazepine? (C) 269–270
Anastasiades, Pavlos *see* **Clark, David M.** *et al* 759–769
Anderson, I. M. *see* **Cowen, P. J.** *et al* 372–379
Angst, Jules *see* **Merikangas, Kathleen Ries** *et al* 342–348
Aoki, Hiroko *see* **Takei, Noriyoshi** *et al* (C) 702–703
Appleby, Louis. Panic and suicidal behaviour (*Editorial*) 719–721
Arnott, Steve and **Nutt, David**. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine (SP) 838–839
Asherson, Philip *see* **McGuffin, Peter** *et al* (*Hypotheses*) 593–599
Asherson, Philip *et al*. Imprinting and anticipation. Are they relevant to genetic studies of schizophrenia? 619–624
Ashford, J. J. Fluvoxamine–prescription event monitoring (C) 852–853
Aubin, F. *see* **Martinot, J. L.** *et al* 27–34
Augustine, M. *see* **Chaudhury, S.** *et al* (SP) 542–543
Avasthi, Ajit *see* **Sikdar, Sudip** *et al* 806–810

Baer, Lee *see* **Holzer, Jacob C.** *et al* 469–473
Bailey, Paul *et al*. Treating negative symptoms (C) 699–700
Ballard, C. G. *et al*. Prevalence of postnatal psychiatric morbidity in mothers and fathers 782–788
Bamford, John *see* **Sharpe, Michael** *et al* 380–386
Bamidele, R. *see* **Gureje, O.** *et al* 481–486
Bancroft, John *see* **Hay, Alistair G.** *et al* 513–516
Bancroft, John. Homosexual orientation (*Editorial*) 437–440
Barkley, C. *see* **Surtees, P. G.** 327–341
Barnes, Thomas R. E. *see* **Duke, Peter J.** *et al* 630–636
Barnes, Thomas R. E. *see* **Halstead, Simon M.** *et al* 177–183
Barnes, Thomas R. E. *see* **Hirsch, Steven R.** (*Comment*) 94–96
Barnes, Thomas R. E. *see* **Liddle, Peter F.** (*Authors' reply*) (C) 702
Barrett, J. S. *see* **Puri, B. K.** *et al* (SP) 841–842
Barton, D. E. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Başoglu, Metin *et al*. Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse 652–659
Başoglu, Metin *et al*. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure 647–652
Bass, Nicholas *see* **Crow, Timothy J.** *et al* 159–164

Batson, Susan C. *see* **Greenfield, Shelly F.** *et al* (SP) 831–834
Beale, Mark D. *see* **Kellner, Charles H.** *et al* (C) 565–566
Bebbington, Paul E. *see* **Jonsson, Bengt** 665–673
Beer, Dominic *et al.* Clozapine-induced neutropenia – or not (C) 850
Behrens, S. *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Belmaker, R. H. *see* **Grisaru, Nimrod** (C) 133–134
Bench, C. J. *see* **McGuire, P. K.** *et al* 459–468
Bentall, Richard P. *see* **Lyon, Helen M.** *et al* 637–646
Berman, Carol W. *see* **Castillo, Pura M.** (SP) 693–696
Biebl, Wilfried *see* **Kinzl, Johann F.** (C) 707
Bigelow, Llewellyn B. *see* **Hyde, Thomas M.** *et al* 494–500
Birchwood, Max *see* **Chadwick, Paul** 190–201
Birtchnell, John. *Battle for the Mind – A Physiology of Conversion and Brain-Washing.* William Sargant (*Books reconsidered*) 273–275
Birtchnell, John. Parental bonding (C) 125
Bishry, Z. *see* **Okasha, A.** *et al* 818–825
Black, Roger J. *see* **Geddes, John R.** *et al* (*Authors' reply*) (C) 564–565
Blacker, C. V. R. *see* **Scott, J.** *et al* (*Current Literature*) 410–415
Blamire, Andrew *see* **David, Anthony** *et al* (*Editorial*) 2–7
Blanchard, M. R. *et al.* The nature of depression among older people in inner London, and the contact with primary care 396–402
Bloch, Sidney *see* **Kissane, David W.** (*Review Article*) 728–740
Boast, Neil and **Coid, Jeremy.** Homosexual erotomania and HIV infection (SP) 842–846
Boccio-Smith, Angela *see* **Crow, Timothy J.** *et al* 159–164
Boom, A. J. *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Booth, I. W. *see* **Rickards, H.** *et al* (SP) 256–261
Botter, P. A. *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Bourne, Harold. The safety and efficacy of clozapine? (C) 267–268
Bovet, Pierre *see* **Günther-Genta, Flavia** *et al* 165–170
Boyarsky, Beth K. *see* **Holzer, Jacob C.** *et al* 469–473
Boyce, Philip *see* **Parker, Gordon** *et al* 316–326
Breiter, Hans *see* **David, Anthony** *et al* (*Editorial*) 2–7
Brewin, Chris R. *see* **Başoglu, Metin** *et al* 652–659
Broadhead, Jeremy C. *see* **Abas, Melanie** *et al* (*Editorial*) 293–296
Brockington, Ian *see* **Craddock, Nick** *et al* 359–364
Brodaty, Henry *see* **Parker, Gordon** *et al* 316–326
Burge, Susan *see* **Craddock, Nick** *et al* 355–358
Burti, Lorenzo *see* **Glick, Ira D.** *et al* (SP) 104–106
Busard, H. L. S. M. *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Byrne, Alan *see* **O'Croinin, Fergus** *et al* (C) 417

Calcedo-Ordoñez, A. *see* **Martinez-Arevalo, M. J.** *et al* (SP) 679–681
Cape, Gavin. Neuroleptic malignant syndrome – a cautionary tale and a surprising outcome (SP) 120–122
Carter, Janet *et al.* Cognitive impairment and clozapine (C) 132–133
Cassano, G. B. *see* **Perugi, G.** *et al* 88–93
Castillo, Pura M. and **Berman, Carol W.** Delusional gross replacement of inanimate objects (SP) 693–696
Chadwick, Paul and **Birchwood, Max.** The omnipotence of voices. A cognitive approach to auditory hallucinations 190–201
Chandra, S. *see* **Chaudhury, S.** *et al* (SP) 542–543
Chaudhury, S. *et al.* Prevalence of Australia antigen (HBsAg) in institutionalised patients with psychosis (SP) 542–543
Chen, Eric Y. H. Neural network model of amnesia (C) 125–126
Chen, Eric Y. H. Verbal fluency and semantic memory in schizophrenia (C) 704
Chen, Wei J. *see* **Faraone, Stephen V.** *et al* 625–629
Chick, J. D. Death during alcohol withdrawal (C) 853
Childs, P. A. *see* **Thompson, C.** *et al* (C) 127
Ciompi, Luc. Affect logic: an integrative model of the psyche and its relations to schizophrenia (suppl. 23) 51–55
Clark, David M. *et al.* A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder 759–769
Clark, Donald *see* **Mackie, James** (C) 421
Clary, Cathryn *see* **Rickels, Karl** *et al* 802–805
Clements, Alison *see* **Asherson, Philip** *et al* 619–624
Clunie, Fiona and **Stewart, John B.** Declining incidence of schizophrenia (C) 564
Cohen, Alex *see* **Edgerton, Robert B.** 222–231
Cohen, Donald J. *see* **Pauls, David L.** *et al* 215–221
Coid, Jeremy *see* **Boast, Neil** (SP) 842–846
Collings, Sunny and **King, Michael.** Ten-year follow-up of 50 patients with bulimia nervosa 80–87
Cooper, Brian and **Eagles, John M.** Folnegović & Folnegović-Šmalc's "Schizophrenia in Croatia: inter-regional differences in prevalence and comment on constant incidence" (*Current Literature*) 97–100
Cope, Susan *see* **Beer, Dominic** *et al* (C) 850
Copeland, J. R. M. *see* **Ravindran, A. V.** *et al* 522–527
Costa, D. C. *see* **Pilowsky, L. S.** *et al* 16–26
Coughlan, A. K. *see* **Williams, C. J.** *et al* (SP) 554–556
Coulouvrat, H. *see* **Guieu, R.** *et al* (SP) 253–255
Cowen, P. J. *et al.* 5-HT_{1A} receptor sensitivity in major depression. A neuroendocrine study with buspirone 372–379
Cox, John L. Perinatal psychiatry: East is East and West is West (C) 420
Craddock, Nick *et al.* Bipolar affective puerperal psychosis associated with consanguinity 359–364
Craddock, Nick *et al.* Familial cosegregation of major affective disorder and Darier's disease (keratosis follicularis) 355–358
Craddock, Nick and **Giuffra, Luis A.** Estimates of risks in relatives of psychotic probands (C) 706–707
Craddock, Nick and **Owen, Mike.** Chromosomal aberrations and bipolar affective disorder 507–512
Craig, T. K. J. Somatisation in general practice (*Author's reply*) (C) 563–564
Craufurd, David *see* **Sugarman, Philip A.** 474–480
Creamer, D. *see* **Shamash, J.** *et al* (C) 849–850
Crow, T. J. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Crow, T. J. Prenatal exposure to influenza as a cause of schizophrenia (*Editorial*) 588–592
Crow, Timothy J. *et al.* An examination of linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal region (Xp22.3) 159–164
Csernansky, John G. *see* **Newcomer, John W.** *et al* (SP) 834–838
Cullberg, Johan. Discussion of Sørensen's and Salokangas's papers (suppl. 23) 121–122
Cullen, P. C. *see* **Ballard, C. G.** *et al* 782–788
Curran, S. Tricyclic-induced seizures and absent ECT response (C) 421

Dalkin, Tim *et al.* Premorbid personality in first-onset psychosis 202–207

Dao-Castellana, M. H. *see* **Martinot, J. L.** *et al* 27–34
Darwish, T. A. *see* **Okasha, A.** *et al* 818–825
David, Anthony *et al.* Functional magnetic resonance imaging (*Editorial*) 2–7
Davies, D. R. Malignant alienation (C) 697–698
Davis, R. *see* **Ballard, C. G.** *et al* 782–788
Deahl, Martin P. *et al.* Psychiatry and war (*Editorial*) 441–442
Dean, C. *see* **Ballard, C. G.** *et al* 782–788
DeLisi, L. E. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
DeLisi, Lynn E. *see* **Crow, Timothy J.** *et al* 159–164
Dell, Susanne *see* **Robertson, Graham** *et al* 55–61
Diamond, Diana and **Doane, Jeri A.** Disturbed attachment and negative affective style. An intergenerational spiral 770–781
DiFiglia, Constance *see* **Peselow, Eric D.** *et al* 208–214
Dinan, Timothy G. Glucocorticoids and the genesis of depressive illness. A psychobiological model 365–371
Doane, Jeri A. *see* **Diamond, Diana** 770–781
Dolan, R. J. *see* **McGuire, P. K.** *et al* 459–468
Dolan, R. J. and **Grasby, P. M.** Exploring the functional role of monoaminergic neurotransmission (*Editorial*) 575–580
Dongen, P. A. M. van *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Duffett, Richard and **Laker, Martin.** Morbidity among social phobics (C) 419
Duinkerke, S. J. *et al.* Treating negative symptoms (*Authors' reply*) (C) 700
Duke, Peter J. *et al.* South Westminster Schizophrenia Survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset 630–636
Duval, Fabrice *see* **Bailey, Paul** *et al* (C) 699–700

Eagles, John M. *see* **Cooper, Brian** (*Current Literature*) 97–100
Eagles, John M. *see* **Geddes, John R.** *et al* (*Authors' reply*) (C) 564–565
Eales, M. J. and **Layeni, A. O.** Exacerbation of obsessive–compulsive symptoms associated with clozapine (SP) 687–688
Eapen, Valsamma and **Robertson, Mary M.** All that tics may not be Tourette's (C) 708
Earnshaw, N. M. *see* **Deahl, Martin P.** *et al* (*Editorial*) 441–442
Edeh, James *see* **Porter, Sally** *et al* (C) 849
Edgerton, Robert B. and **Cohen, Alex.** Culture and schizophrenia: the DOSMD challenge 222–231
Edwards, J. Guy *et al.* Prescription-event monitoring of 10 401 patients treated with fluvoxamine 387–395
Elander, James *see* **Porter, Sally** *et al* (C) 849
El Dawla, A. Seif *see* **Okasha, A.** *et al* 818–825
El-Dosoky, A. *see* **Puri, B. K.** *et al* (SP) 841–842
Ell, P. J. *see* **Pilowsky, L. S.** *et al* 16–26
Emsellem, Helene A. *see* **Hyde, Thomas M.** *et al* 811–817
Escobar, Javier I. *see* **Randolph, Eugenia T.** *et al* 501–506
Eth, Spencer *see* **Randolph, Eugenia T.** *et al* 501–506
Eyers, Kerrie *see* **Parker, Gordon** *et al* 316–326
Eysenck, Michael W. *Perception and Communication.* D. E. Broadbent (*Books reconsidered*) 711–712

Faraone, Stephen V. *et al.* Gender differences in age at onset of schizophrenia 625–629
Farmer, Anne *see* **McGuffin, Peter** *et al* (*Hypotheses*) 593–599
Fassbender, K. *see* **Kellner, M.** *et al* (C) 132
Fätkenheuer, B. *see* **Hafner, H.** *et al* (suppl. 23) 29–38
Faustman, William O. *see* **Newcomer, John W.** *et al* (SP) 834–838
Fennig, S. *et al.* Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive–compulsive disorder (SP) 839–841
Ferguson-Smith, M. A. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Fieve, Ronald R. *see* **Peselow, Eric D.** *et al* 208–214, 349–354
Fink, Max. Administrative problems limiting electroconvulsive therapy (C) 850–851
Fombonne, Eric. The Chartres study: I. Prevalence of psychiatric disorders among French school-aged children 69–79
Fox, Ira *see* **Rickels, Karl** *et al* 802–805
Frackowiak, R. S. J. *see* **McGuire, P. K.** *et al* 459–468
Franz, Michael *et al.* Treatment of catatonia with intravenous biperidene (C) 847–848
Frazer, Sheila J. and **Roberts, Jeremy M.** Three cases of Capgras' syndrome (SP) 557–559
Freeman, Hugh. Schizophrenia and city residence (suppl. 23) 39–50
Frith, C. D. *see* **McGuire, P. K.** *et al* 459–468

Gallhofer, Bernd *see* **Franz, Michael** *et al* (C) 847–848
Gangadhar, B. N. and **Janakiramaiah, N.** Antidepressant effects of ECT (C) 123–124
Gardner, Russell, Jr *see* **Price, John** *et al* 309–315
Garralda, M. E. Chronic physical illness and emotional disorder in childhood (*Editorial*) 8–10
Gattaz, W. F. *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Geddes, John R. *et al.* Declining incidence of schizophrenia (*Authors' reply*) (C) 564–565
Gelder, Michael *see* **Adams, Clive** (*Editorial*) 433–436
Gelder, Michael *see* **Clark, David M.** *et al* 759–769
Gewirtz, George *et al.* Results of computerised tomography during first admission for psychosis 789–795
Gilbert, Paul *see* **Price, John** *et al* 309–315
Gilbert, Sidsel and **Ugelstad, Endre.** Patients' own contributions to long-term supportive psychotherapy in schizophrenic disorders (suppl. 23) 84–88
Gill, Michael *see* **Asherson, Philip** *et al* 619–624
Giuffra, Luis A. *see* **Craddock, Nick** (C) 706–707
Glazebrook, Cris *see* **Dalkin, Tim** *et al* 202–207
Glick, Ira D. *et al.* Effectiveness in psychiatric care. III: Psychoeducation and outcome for patients with major affective disorder and their families (SP) 104–106
Glover, Vivette *et al.* Mild hypomania (the highs) can be a feature of the first postpartum week. Association with later depression 517–521
Glynn, Shirley M. *see* **Randolph, Eugenia T.** *et al* 501–506
Gold, R. *see* **Vaughan, K.** *et al* 533–541
Goldberg, Terry E. *see* **Hyde, Thomas M.** *et al* 494–500
Goldstein, Jill M. *see* **Faraone, Stephen V.** *et al* 625–629
Goodburn, S. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Goodman, Wayne K. *see* **Holzer, Jacob C.** *et al* 469–473
Goodwin, Guy M. Recurrence of mania after lithium withdrawal (*Editorial*) 149–152
Gossop, Michael *et al.* Cocaine: patterns of use, route of administration, and severity of dependence 660–664
Gossop, Michael *et al.* A ratio estimation method for determining the prevalence of cocaine use (SP) 676–679
Gossop, Michael *et al.* Sex differences in patterns of drug taking behaviour. A study at a London community drug team (SP) 101–104
Gottesman, Irving I. *see* **Thapar, Anita** *et al* 747–758
Grasby, P. M. *see* **Dolan, R. J.** (*Editorial*) 575–580

Greenfield, Shelly F. *et al.* Childhood abuse in first-episode psychosis (SP) 831–834
Griffiths, Paul *see* **Gossop, Michael** *et al* 660–664
Griffiths, Paul *see* **Gossop, Michael** *et al* (SP) 101–104, 676–679
Grimley Evans, J. *see* **O'Mahony, Denis** (C) 705–706
Grisaru, Nimrod and **Belmaker, R. H.** Lithium dosage and inositol levels (C) 133–134
Grounds, Adrian *see* **Robertson, Graham** *et al* 55–61
Guieu, R. *et al.* Objective evaluation of pain perception in patients with schizophrenia (SP) 253–255
Gulbenkian, Gary *see* **Peselow, Eric D.** *et al* 349–354
Gunaratne, I. J. *see* **Jancar, J.** (SP) 691–693
Gunn, John *see* **Maden, Tony** *et al* 44–54
Gunn, John. Brain, mind and behaviour (C) 416
Günther-Genta, Flavia *et al.* Obstetric complications and schizophrenia. A case-control study 165–170
Gureje, O. *et al.* Heritability of schizophrenia. A controlled family history investigation in Nigeria 481–486
Guscott, R. and **Taylor, L.** Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency (*Review Article*) 741–746

Haaften, A. J. van *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Hackmann, Ann *see* **Clark, David M.** *et al* 759–769
Hadzi-Pavlovic, Dusan *see* **Parker, Gordon** *et al* 316–326
Häfner, H. *et al.* The epidemiology of early schizophrenia. Influence of age and gender on onset and early course (suppl. 23) 29–38
Hall, Peter. Anorexic siblings (C) 268–269
Halstead, Simon M. *et al.* Akathisia: prevalence and associated dysphoria in an in-patient population 177–183
Hamlin, G. W. *see* **Parry, A. K.** *et al* (SP) 689–691
Harris, Brian. Biological and hormonal aspects of postpartum depressed mood (*Editorial*) 288–292
Harrison, Glynn *see* **Dalkin, Tim** *et al* 202–207
Hatcher, Simon *see* **Owens, David** *et al* (C) 697
Hatcher, Simon. Debt and deliberate self-poisoning (SP) 111–114
Hawton, K. *see* **Morgan, H. G.** (C) 126–127
Hawton, Keith *see* **Sharpe, Michael** *et al* 380–386
Hay, Alistair G. *et al.* Affective symptoms in women attending a menopause clinic 513–516
Heiden, W. an der *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Hemmings, Gwynneth P. *see* **Xu, Hai-Min** *et al* (SP) 251–253
Hickie, Ian *see* **Parker, Gordon** *et al* 316–326
Hirsch, Steven R. and **Barnes, Thomas R. E.** Clinical use of high-dose neuroleptics (*Comment*) 94–96
Hohlfeld, Patrick *see* **Günther-Genta, Flavia** *et al* 165–170
Holzer, Jacob C. *et al.* Obsessive–compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients 469–473
Honer, William G. *see* **Gewirtz, George** *et al* 789–795
Horne, Andrew S. Brain, mind and behaviour (C) 416–417
Hotopf, Matthew. Seasonal affective disorder, environmental hypersensitivity and somatisation (SP) 246–248
House, Allan *see* **Owens, David** *et al* (C) 697
House, Allan *see* **Sharpe, Michael** *et al* 380–386
Howland, Robert B. The rarity of mania in Down's syndrome (C) 422
Hunt, Neil. Is there a lithium withdrawal syndrome? (C) 418–419
Huttunen, Matti O. *et al.* Prenatal factors in the pathogenesis of schizophrenia (suppl. 23) 15–19
Hyde, Thomas M. *et al.* Electroencephalographic abnormalities in monozygotic twins with Tourette's syndrome 811–817
Hyde, Thomas M. *et al.* Is there cognitive decline in schizophrenia? A cross-sectional study 494–500

Ineichen, Bernard. Psychiatric morbidity and compulsory admission (C) 267
Inman, William H. W. *see* **Edwards, J. Guy** *et al* 387–395
Iyo, Rie *see* **Takei, Noriyoshi** *et al* (C) 702–703

Jadhav, Sushrut *see* **Littlewood, Roland** (C) 419
James, Basil *see* **Robertson, Mary M.** *et al* (SP) 263–266
James, Katie *see* **Robertson, Graham** *et al* 55–61
Janakiramaiah, N. *see* **Gangadhar, B. N.** (C) 123–124
Jancar, J. and **Gunaratne, I. J.** Dysthymia and mental handicap (SP) 691–693
Jansen, A. A. I. *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
John, Carolyn *see* **Kingdon, David** *et al* (*Editorial*) 581–587
Johns, Andrew *see* **Porter, Sally** *et al* (C) 849
Johnston, D. G. *see* **Shamash, J.** *et al* (C) 849–850
Johnstone, Eve C. *see* **Hay, Alistair G.** *et al* 513–516
Jones, G. H. *see* **O'Flaithbheartaigh, S.** *et al* (SP) 684–686
Jones, J. R. *see* **Adeniran, R. A.** (SP) 559–561
Jones, N. *see* **Deahl, Martin P.** *et al* (*Editorial*) 441–442
Jönsson, Bengt and **Bebbington, Paul E.** What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment 665–673
Joseph, Anil *see* **Michael, Albert** *et al* (SP) 244–246
Joseph, Philip L. A. Psychiatric assessment at the magistrates' court (*Editorial*) 722–724
Jung, Chul-Ho *see* **Park, Jonghan** *et al* 796–801

Kaleva, Merja *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Kambhampati, R. Krishna *see* **Keshavan, Matcheri S.** *et al* (SP) 118–120
Kane, John M. The use of higher-dose antipsychotic medication (*Editorial*) 431–432
Kaney, Sue *see* **Lyon, Helen M.** *et al* 637–646
Kanzow, Walter T. *see* **Franz, Michael** *et al* (C) 847–848
Kay, Ronald W. Geomagnetic storms: association with incidence of depression as measured by hospital admission 403–409
Kazamatsuri, Hajime *see* **Takei, Noriyoshi** *et al* (C) 702–703
Kellner, Charles H. *et al.* Onset of the antidepressant effect of ECT (C) 565–566
Kellner, M. *et al.* DIDMOAD (Wolfram) syndrome (C) 132
Kennerknecht, I. *see* **Kellner, M.** *et al* (C) 132
Kerwin, R. W. *see* **Pilowsky, L. S.** *et al* 16–26
Kerwin, R. W. The new atypical antipsychotics (*Editorial*) 141–148
Keshavan, Matcheri S. *et al.* Creatine kinase elevations with clozapine (SP) 118–120
Khalil, A. H. *see* **Okasha, A.** *et al* 818–825
Khumalo-Sakatukwa, Gertrude *see* **Abas, Melanie** *et al* (*Editorial*) 293–296
Kiliç, Cengiz *see* **Başoglu, Metin** *et al* 647–652, 652–659
Kim, Chul-Eung *et al.* Month of birth and schizophrenia in Korea. Sex, family history and handedness (SP) 829–831
King, Michael *see* **Collings, Sunny** 80–87
Kingdon, David *et al.* Cognitive behaviour therapy of schizophrenia (*Editorial*) 581–587
Kinzl, Johann F. and **Biebl, Wifried.** Childhood sexual abuse and mental health (C) 707

Kirk, Helen E. *see* **Reid, Andrew H.** (C) 708–709
Kissane, David W. and **Bloch, Sidney**. Family grief (*Review Article*) 728–740
Klein, R. *see* **Kellner, M.** *et al* (C) 132
Kleinman, Joel E. *see* **Hyde, Thomas M.** *et al* 494–500
Ko, Hyo Jin *see* **Park, Jonghan** *et al* 796–801
Kolbrener, Meredith L. *see* **Greenfield, Shelly F.** *et al* (SP) 831–834
Kringlen, Einar. Theory of schizophrenia: comments (suppl. 23) 62–64
Kuch, Klaus *see* **Başoglu, Metin** *et al* 647–652
Kulhara, Parmanand *see* **Sikdar, Sudip** *et al* 806–810
Kunugi, Hiroshi *see* **Takei, Noriyoshi** *et al* (C) 702–703
Kurian, Bobby *see* **Craddock, Nick** *et al* 355–358

Laarhoven, J. H. M. van *see* **Duinkerke, S. J.** *et al* (*Authors' reply*) (C) 700
Lahti, Ilpo *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Laker, Martin *see* **Duffett, Richard** (C) 419
Laksy, Kristian *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Layeni, A. O. *see* **Eales, M. J.** (SP) 687–688
Leckman, James F. *see* **Holzer, Jacob C.** *et al* 469–473
Leckman, James F. *see* **Pauls, David L.** *et al* 215–221
Lecrubier, Y. *see* **Martinot, J. L.** *et al* 27–34
Lee, Alan *see* **Stokes, Philip** *et al* (C) 565
Lee, Alan and **Parker, Gordon**. The peer review of "Outcome of depression in psychiatric settings" (*Peer Review*) 305–308
Lee, Alan S. *see* **Moorhead, Stephen R. J.** *et al* (SP) 682–683
Lee, Young-Sook *see* **Kim, Chul-Eung** *et al* (SP) 829–831
Leff, Julian. Working with the families of schizophrenic patients (suppl. 23) 71–76
Leggo, J. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Lehner, Thomas *see* **Crow, Timothy J.** *et al* 159–164
Lehtinen, Klaus. Need-adapted treatment of schizophrenia: family interventions (suppl. 23) 89–96
Lehtonen, Johannes. From dualism to psychobiological interaction. A comment on the study by Tienari and his co-workers (suppl. 23) 27–28
Leong, Gregory B. *see* **Randolph, Eugenia T.** *et al* 501–506
Levy, Raymond. Alzheimer's disease and Lewy body dementia (C) 268
Levy, Raymond and **Almeida, Osvaldo P.**. Late-onset schizophrenia versus late paraphrenia (C) 127–128
Lewis, Shôn. ICD–10: a neuropsychiatrist's nightmare? (*Editorial*) 157–158
Li, S. H. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Liberman, Robert P. *see* **Randolph, Eugenia T.** *et al* 501–506
Liddle, Peter *see* **Glover, Vivette** *et al* 517–521
Liddle, Peter F. and **Barnes, Thomas R. E.** Tardive dyskinesia as a risk factor for negative symptoms (*Authors' reply*) (C) 702
Lillywhite, A. R. *et al*. Successful treatment of night terrors and somnambulism with paroxetine (SP) 551–554
Lim, Young-Hee *see* **Kim, Chul-Eung** *et al* (SP) 829–831
Linaker, Olav M. Assaultiveness among institutionalised adults with mental retardation 62–68
Lindesay, James. Psychosis and cannabis (C) 566
Lishman, Alwyn *see* **McGilchrist, Iain** *et al* (SP) 261–263
Littlewood, Roland and **Jadhav, Sushrut**. Ethnic nomenclature (C) 419
Loc'h, C. *see* **Martinot, J. L.** *et al* 27–34
Löf, Kari *see* **Seppä, Kaija** *et al* (SP) 544–546
Löffler, W. *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Lofthouse, R. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Lofthouse, Raymond *see* **Crow, Timothy J.** *et al* 159–164
Lyon, Helen M. *et al*. The defensive function of persecutory delusions. Evidence from attribution tasks 637–646

Mbape, Priscilla *see* **Abas, Melanie** *et al* (*Editorial*) 293–296
McClelland, R. J. *see* **McVicker, R. W.** *et al* 528–532
McCreadie, Robin G. and **Ohaeri, Jude U.** Movement disorder in never and minimally treated Nigerian schizophrenic patients 184–189
McDougle, Christopher J. *see* **Holzer, Jacob C.** *et al* 469–473
McGilchrist, Iain *et al*. 'Dyschronia' in a patient with Tourette's syndrome presenting as maternal neglect (SP) 261–263
McGuffin, Peter *see* **Asherson, Philip** *et al* 619–624
McGuffin, Peter *see* **Craddock, Nick** *et al* 355–358, 359–364
McGuffin, Peter *see* **Thapar, Anita** *et al* 747–758
McGuffin, Peter *et al*. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? (*Hypotheses*) 593–599
McGuire, P. K. *et al*. Functional anatomy of obsessive–compulsive phenomena 459–468
MacHale, Siobhan and **Phanjoo, André L.** SSRIs to treat sexual dysfunction (C) 854
Macher, Jean-Paul *see* **Bailey, Paul** *et al* (C) 699–700
Machon, Ricardo A. *see* **Huttunen, Matti O.** *et al* (suppl. 23) 15–19
McKenna, P. J. *see* **Thornton, A.** (SP) 115–118
Mackie, James *see* **Clark, Donald** (C) 421
McVicker, R. W. *et al*. Prevalence and associated features of epilepsy in adults with Down's syndrome 528–532
Maden, Tony. Psychiatric disorder in women serving a prison sentence 44–54
Malla, Ashok K. and **Norman, Ross M. G.** Prodromal symptoms in schizophrenia 487–493
Mann, A. H. *see* **Blanchard, M. R.** *et al* 396–402
Mant, Rebecca *see* **Craddock, Nick** *et al* 359–364
Markar, H. *see* **Thalayasingam, S.** *et al* (C) 417–418
Marks, I. M. *see* **McGuire, P. K.** *et al* 459–468
Marks, Isaac M. *see* **Başoglu, Metin** *et al* 647–652, 652–659
Martin, J. *see* **Mullen, Paul E.** 35–43
Martinez-Arevalo, M. J. *et al*. Cannabis consumption as a prognostic factor in schizophrenia (SP) 679–681
Martinot, J. L. *et al*. Central D_2 receptors and negative symptoms of schizophrenia 27–34
Maurer, K. *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Maziere, B. *see* **Martinot, J. L.** *et al* 27–34
Mazoyer, B. *see* **Martinot, J. L.** *et al* 27–34
Medley, Ian *see* **Dalkin, Tim** *et al* 202–207
Mednick, Sarnoff A. *see* **Huttunen, Matti O.** *et al* (suppl. 23) 15–19
Mercer, Michael *see* **Robertson, Mary M.** *et al* (SP) 263–266
Merikangas, Kathleen Ries *et al*. Heterogeneity of depression. Classification of depressive subtypes by longitudinal course 342–348
Miall, L. *see* **Shamash, J.** *et al* (C) 849–850
Michael, Albert *et al*. Delusions of pregnancy (SP) 244–246
Michel, Konrad and **Spuhler, Thomas**. Benzodiazepine fatal poisonings (C) 128–129
Middleton, Hugh *see* **Clark, David M.** *et al* 759–769
Miller, L. Stephen *see* **Newcomer, John W.** *et al* (SP) 834–838
Mitchell, Alexander J. Glucocorticoids and the genesis of depressive illness (C) 853–854
Mitchell, Philip *see* **Parker, Gordon** *et al* 316–326
Mizuki, Tunetaka *see* **Terao, Takeshi** *et al* (SP) 109–111
Mohan, R. N. *see* **Ballard, C. G.** *et al* 782–788
Molyneux, Andrew *see* **Sharpe, Michael** *et al* 380–386

Moncrieff, Joanna. Association between sexual and substance abuse (C) 847
Moon, C. A. L. *see* **Scott, J.** *et al* (*Current Literature*) 410–415
Moorhead, Stephen R. J. and **Lee, Alan S.** ANA negative systemic lupus erythematosus (SP) 682–683
Morgan, Gethin *see* **Watts, Darryl** (*Editorial*) 11–15
Morgan, H. G. "Mental Illness: The Fundamental Facts" (*Editorial*) 725–727
Morgan, H. G. Suicide (update 1988) (*Reading about*) 271–272
Morgan, H. G. and **Hawton, K.** Suicide prevention (C) 126–127
Morgan, H. G. and **Watts, D.** Malignant alienation (*Authors' reply*) (C) 698
Moriarty, John *see* **Varma, Anoop Ranjan** *et al* (C) 124–125
Moring, Juha *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Mullen, Paul E. and **Martin, J.** Jealousy: a community study 35–43
Murphy, Patrice *see* **Dalkin, Tim** *et al* 202–207
Murray, R. M. *see* **Pilowsky, L. S.** *et al* 16–26
Musetti, L. *see* **Perugi, G.** *et al* 88–93

Naarala, Mikko *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Naisberg Fennig, S. *see* **Fennig, S.** *et al* (SP) 839–841
Nanko, Shinichiro *see* **Takei, Noriyoshi** *et al* (C) 702–703
Nawroz, Safia *see* **Hyde, Thomas M.** *et al* 494–500
Newcomer, John W. *et al*. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria (SP) 834–838
Noh, In-Young *see* **Kim, Chul-Eung** *et al* 829–831
Norman, Ross M. G. *see* **Malla, Ashok K.** 487–493
Noshirvani, Homa *see* **Başoglu, Metin** *et al* 647–652
Nutt, D. J. *see* **Lillywhite, A. R.** *et al* (SP) 551–554
Nutt, David *see* **Arnott, Steve** (SP) 838–839

O'Brien, L. Stephen. What will be the psychiatric consequences of the war in Bosnia? (*Editorial*) 443–447
O'Croinin, Fergus *et al*. Life events and relapse in bipolar disorder (C) 417
O'Donovan, Michael C. *see* **Thapar, Anita** *et al* 747–758
O'Flaithbheartaigh, S. *et al*. Schizophrenic psychosis and associated aqueduct stenosis (SP) 684–686
Ohaeri, Jude U. *see* **McCreadie, Robin G.** 184–189
Ohji, Taro *see* **Terao, Takeshi** *et al* (SP) 109–111
Okasha, A. *et al*. Panic disorder. An overlapping or independent entity? 818–825
Okonogi, Keigo *see* **Glick, Ira D.** *et al* (SP) 104–106
O'Mahony, Denis and **Grimley Evans, J.** Diogenes syndrome by proxy (C) 705–706
Ormerod, L. P. *see* **Parry, A. K.** *et al* (SP) 689–691
Osborn, Madeline *see* **Thomas, Christopher S.** *et al* (*Authors' reply*) (C) 267
O'Shea, Brian. Pain and seasonal affective disorder (C) 421–422
Ostrem, Jill L. *see* **Hyde, Thomas M.** *et al* 494–500
O'Sullivan, Geraldine *see* **Başoglu, Metin** *et al* 647–652
Ott, Jurg *see* **Crow, Timothy J.** *et al* 159–164
Owen, Michael *see* **Asherson, Philip** *et al* 619–624
Owen, Michael *see* **McGuffin, Peter** *et al* (*Hypotheses*) 593–599
Owen, Michael J. *see* **Thapar, Anita** *et al* 747–758
Owen, Mike *see* **Craddock, Nick** 507–512
Owen, Mike *see* **Craddock, Nick** *et al* 355–358, 359–364
Owens, David *et al*. Points of style (C) 697

Paillère-Martinot, M. L. *see* **Martinot, J. L.** *et al* 27–34
Pallen, Alphie *see* **Michael, Albert** *et al* (SP) 244–246
Pantelis, Christos *see* **Duke, Peter J.** *et al* 630–636
Parfitt, Elizabeth *see* **Craddock, Nick** *et al* 359–364
Park, Jonghan *et al*. Dementia among the elderly in a rural Korean community 796–801
Park, S. H. *see* **Kim, Chul-Eung** *et al* (SP) 829–831
Park, Young Nam *see* **Park, Jonghan** *et al* 796–801
Parker, Gordon *see* **Lee, Alan** (*Peer Review*) 305–308
Parker, Gordon *et al*. Defining melancholia: properties of a refined sign-based measure 316–326
Parry, A. K. *et al*. Recurrent sinus arrest in association with neuroleptic malignant syndrome (SP) 689–691
Pato, M. *see* **Fennig, S.** *et al* (SP) 839–841
Paton, Carol *see* **Beer, Dominic** *et al* (C) 850
Paulley, J. W. Somatisation in general practice (C) 562–563
Pauls, David L. *see* **Robertson, Mary M.** *et al* (SP) 263–266
Pauls, David L. *et al*. Evidence against a genetic relationship between Tourette's syndrome and anxiety, depression, panic and phobic disorders 215–221
Paz, George G. *see* **Randolph, Eugenia T.** *et al* 501–506
Pearce, Gillian L. *see* **Edwards, J. Guy** *et al* 387–395
Peet, Malcolm. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants (SP) 549–550
Perugi, G. *et al*. Social adjustment in panic–agoraphobic patients reconsidered 88–93
Peselow, Eric D. *et al*. Lithium prophylaxis of bipolar illness. The value of combination treatment 208–214
Peselow, Eric D. *et al*. Personality traits during depression and after clinical recovery 349–354
Phanjoo, André L. *see* **MacHale, Siobhan** (C) 854
Piccinelli, Marco and **Wilkinson, Greg**. Outcome of depression in psychiatric settings (*Review Article*) 297–304
Pichot, Pierre. Nosological models in psychiatry (*Lecture*) 232–240
Pilowsky, L. S. *et al*. D_2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An ^{123}I-IBZM single photon emission computerised tomography study 16–26
Piper, August, Jr. Multiple personality disorder (*Review Article*) 600–612
Porter, Sally *et al*. Risk of HIV for women who inject drugs (C) 849
Poulter, Mark *see* **Crow, Timothy J.** *et al* 159–164
Power, A. C. *see* **Cowen, P. J.** *et al* 372–379
Power-Smith, Parsley. Beneficial sexual side-effects from fluoxetine (SP) 249–250
Powis, Beverly *see* **Gossop, Michael** *et al* 660–664
Powis, Beverly *see* **Gossop, Michael** *et al* (SP) 676–679
Prendergast, M. *see* **Rickards, H.** *et al* (SP) 256–261
Prettyman, Richard. Lithium neurotoxicity at subtherapeutic serum levels (C) 123
Price, John *et al*. The social competition hypothesis of depression 309–315
Price, Lawrence H. *see* **Holzer, Jacob C.** *et al* 469–473
Priest, R. G. Improving the management and knowledge of depression (*Editorial*) 285–287
Pritchett, John T. *see* **Kellner, Charles H.** *et al* (C) 565–566
Puri, B. K. *et al*. Self-inflicted intracranial injury (SP) 841–842

Raheja, S. K. *see* **Thompson, C.** *et al* (C) 127
Räkköläinen, Viljo *see* **Aaltonen, Jukka** (suppl. 23) 97–102
Randolph, Christopher *see* **Hyde, Thomas M.** *et al* 811–817

Randolph, Eugenia T. *et al.* Behavioural family management in schizophrenia. Outcome of a clinic-based intervention 501–506
Ravindran, A. V. *et al.* Semi-structured depression scale sensitive to change with treatment for use in the elderly 522–527
Reid, Andrew H. Psychiatry and learning disability 613–618
Reid, Andrew H. and **Kirk, Helen E.** Brain, mind and behaviour (C) 708–709
Rickards, H. *et al.* Psychiatric presentation of Crohn's disease. Diagnostic delay and increased morbidity (SP) 256–261
Rickels, Karl *et al.* Nefazodone and imipramine in major depression: a placebo-controlled trial 802–805
Rickler, Kenneth C. *see* **Hyde, Thomas M.** *et al* 811–817
Riecher-Rössler, A. *see* **Häfner, H.** *et al* (suppl. 23) 29–38
Roberts, Jeremy M. *see* **Frazer, Sheila J.** (SP) 557–559
Robertson, Graham *et al.* Psychotic men remanded in custody to Brixton Prison 55–61
Robertson, Mary M. *see* **Eapen, Valsamma** (C) 708
Robertson, Mary M. *et al.* Tourette's syndrome in New Zealand. A postal survey (SP) 263–266
Robinson, S. *see* **Shamash, J.** *et al* (C) 849–850
Rodger, Colin R. *et al.* Is there a delay in the onset of the antidepressant effect of electroconvulsive therapy? (SP) 106–109
Rogers, T. D. and **Waxman, David**. Whorwell *et al*'s "Physiological effects of emotion: assessment via hypnosis" (*Current Literature*) 241–243
Rohde, Peter *see* **Price, John** *et al* 309–315
Rollin, Henry. Hypodermic injections of brain extract in mental diseases. By R.P. Ryan (*A hundred years ago*) 270
Rollin, Henry. Kleptomania (*A hundred years ago*) 709–710
Rollin, Henry. A Neapolitan private asylum. By Fraser Nicolson (*A hundred years ago*) 855
Rollin, Henry. The Opium Commission (*A hundred years ago*) 567
Rollin, Henry. The prevention of suicide (*A hundred years ago*) 423
Rollin, Henry. Reports of lunatic asylums for 1892 (*A hundred years ago*) 134
Ross, C. A. *see* **Rubinsztein, D. C.** *et al* (C) 851–852
Rowe, C. E. Attachment theory (C) 130–131
Rubinsztein, D. C. *et al.* B37 repeats are normal in most schizophrenic patients (C) 851–852

Saarento, Outi *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Sacks, Michael *see* **Glick, Ira D.** *et al* (SP) 104–106
Saleem, P. T. *see* **Parry, A. K.** *et al* (SP) 689–691
Salkovskis, Paul M. *see* **Clark, David M.** *et al* 759–769
Salokangas, Raimo K. R. Community care and need for treatment of schizophrenic patients in Finland (suppl. 23) 115–120
Salonen, Simo. Comment on Vamik Volkan's paper (suppl. 23) 83
Salzmann, M. M. Variations on the theme of euthanasia (C) 131
Samuélian, J. C. *see* **Guieu, R.** *et al* (SP) 253–255
Sandercock, Peter *see* **Sharpe, Michael** *et al* 380–386
Sandler, Merton *see* **Glover, Vivette** *et al* 517–521
Sanfilipo, Michael P. *see* **Peselow, Eric D.** *et al* 208–214, 349–354
Sargeant, Mathew *see* **Asherson, Philip** *et al* 619–624
Schweizer, Edward *see* **Rickels, Karl** *et al* 802–805
Scott, Allan I. F. *see* **Rodger, Colin R.** *et al* (SP) 106–109
Scott, J. *et al.* A. I. F. Scott & C. P. L. Freeman's "Edinburgh primary care depression study" (*Current Literature*) 410–415
Seagroatt, Valerie *see* **Sharpe, Michael** *et al* 380–386
Seifert, Ruth *see* **Walker, Zuzana** (SP) 826–828
Seitamaa, Markku *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Selten, J.-P. C. J. and **Slaets, J. P. J.** Evidence against maternal influenza as a risk factor for schizophrenia (SP) 674–676
Seppä, Kaija *et al.* Hidden alcohol abuse among women (SP) 544–546
Shah, Tarulata *see* **Crow, Timothy J.** *et al* 159–164
Shamash, J. *et al.* Dysphagia in the neuroleptic malignant syndrome (C) 849–850
Shaner, Andrew L. *see* **Randolph, Eugenia T.** *et al* 501–506
Shanks, O.E. P. *see* **McVicker, R. W.** *et al* 528–532
Sharif, Zafar *see* **Gewirtz, George** *et al* 789–795
Sharpe, Michael *et al.* Depressive disorders in long-term survivors of stroke. Associations with demographic and social factors, functional status, and brain lesion volume 380–386
Shaw, Stephen H. How abuse has affected me (C) 706
Shields, Gail *see* **Crow, Timothy J.** *et al* 159–164
Shohdy, A. *see* **Okasha, A.** *et al* 818–825
Shulman, Kenneth I. and **Tohen, Mauricio**. Unipolar mania reconsidered: evidence from an elderly cohort (SP) 547–549
Sikdar, Sudip *et al.* Combined chlorpromazine and electroconvulsive therapy in mania 806–810
Sillanaukee, Pekka *see* **Seppä, Kaija** *et al* (SP) 544–546
Simonini, E. *see* **Perugi, G.** *et al* 88–93
Simpson, Michael A. Severity and the stressor criterion in post-traumatic stress disorder (C) 704–705
Sinclair, David *see* **Seppä, Kaija** *et al* (SP) 544–546
Singh, Hariwir *see* **Sikdar, Sudip** *et al* 806–810
Slaets, J. P. J. *see* **Selten, J.-P. C. J.** (SP) 674–676
Sloman, Leon *see* **Price, John** *et al* 309–315
Sørensen, Tom. The intricacy of the ordinary (suppl. 23) 108–114
Sorri, Anneli *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Speller, Jeremy C. *see* **Halstead, Simon M.** *et al* 177–183
Spuhler, Thomas *see* **Michel, Konrad** (C) 128–129
Squires-Wheeler, Elizabeth *see* **Gewirtz, George** *et al* 789–795
St Clair, David. Genetics of Alzheimer's disease (*Editorial*) 153–156
Stecker, John *see* **Keshavan, Matcheri S.** *et al* (SP) 118–120
Steels, Mark *see* **Stokes, Philip** *et al* (C) 565
Stephens, Sue *see* **Porter, Sally** *et al* (C) 849
Stewart, John B. *see* **Clunie, Fiona** (C) 564
Stokes, Philip *et al.* Maintenance therapy for schizophreniform disorder (C) 565
Stone, Kit *see* **Thomas, Christopher S.** *et al* (*Authors' reply*) (C) 267
Strachan, Angus *see* **Randolph, Eugenia T.** *et al* 501–506
Strakowski, Stephen M. *see* **Greenfield, Shelly F.** *et al* (SP) 831–834
Strang, John *see* **Gossop, Michael** *et al* 660–664
Strang, John *see* **Gossop, Michael** *et al* (SP) 101–104, 676–679
Strauss, John S. The person with schizophrenia as a person. II: approaches to the subjective and complex (suppl. 23) 103–107
Strian, F. *see* **Kellner, M.** *et al* (C) 132
Strong, David *see* **Hyde, Thomas M.** *et al* 494–500
Sugarman, Philip A. and **Craufurd, David**. Schizophrenia in the Afro-Caribbean community 474–480
Surtees, P. G. and **Barkley, C.** Future imperfect: the long-term outcome of depression 327–341
Swinson, Richard P. *see* **Başoglu, Metin** *et al* 647–652, 652–659

Swinton, Mark *see* **Maden, Tony** *et al* 44–54
Syrota, A. *see* **Martinot, J. L.** *et al* 27–34
Syvälahti, E. K. G. Biological factors in schizophrenia. Structural and functional aspects (suppl. 23) 9–14

Takei, Noriyoshi *et al.* Low serum cholesterol and suicide attempts (C) 702–703
Tarrier, N. *see* **Vaughan, K.** *et al* 533–541
Taylor, Alyx *see* **Glover, Vivette** *et al* 517–521
Taylor, Celia *see* **Asherson, Philip** *et al* 619–624
Taylor, Chris. Managing the manipulative therapist (C) 698–699
Taylor, Colin *see* **Gossop, Michael** *et al* (SP) 676–679
Taylor, L. *see* **Guscott, R.** (*Review Article*) 741–746
Taylor, Mark *see* **Wright, Pádraig** (C) 700–701
Taylor, Simon J. Debt and deliberate self-harm (C) 848–849
Taylor, Simon J. Tardive dyskinesia as a risk factor for negative symptoms (C) 701–702
Terao, Takeshi *et al.* Antidepressant effect of lithium in patients with systemic lupus erythematosus and cerebral infarction, treated with corticosteroid (SP) 109–111
Thalayasingam, S. *et al.* Is there a lithium withdrawal syndrome? (C) 417–418
Thapar, Anita *et al.* The genetics of mental retardation 747–758
Thomas, Christopher S. *et al.* Psychiatric morbidity and compulsory admission (*Authors' reply*) (C) 267
Thomas, J. M. *see* **Scott, J.** *et al* (*Current Literature*) 410–415
Thomas, Phil *see* **Craddock, Nick** *et al* 355–358
Thomas, Phil *see* **Thomas, Christopher S.** *et al* (*Authors' reply*) (C) 267
Thompson, C. The use of high-dose antipsychotic medication (*Consensus Statement*) 448–458
Thompson, C. *et al.* Seasonal affective disorder (C) 127
Thornicroft, Graham *see* **Carter, Janet** *et al* (C) 132–133
Thornton, A. and **McKenna, P. J.** Acute dystonic reactions complicated by psychotic phenomena (SP) 115–118
Thrasher, Sian *see* **Carter, Janet** *et al* (C) 132–133
Tienari, Pekka *et al.* The Finnish adoptive family study of schizophrenia. Implications for family research (suppl. 23) 20–26
Tohen, Mauricio *see* **Greenfield, Shelly F.** *et al* (SP) 831–834
Tohen, Mauricio *see* **Shulman, Kenneth I.** (SP) 547–549
Trimble, Michael R. *see* **Varma, Anoop Ranjan** *et al* (C) 124–125
Tsuang, Ming T. *see* **Faraone, Stephen V.** *et al* 625–629
Turkington, Douglas *see* **Kingdon, David** *et al* (*Editorial*) 581–587

Ugelstad, Endre *see* **Gilbert, Sidsel** (suppl. 23) 84–88

Van Vort, Walter *see* **Randolph, Eugenia T.** *et al* 501–506
Varma, Anoop Ranjan *et al.* Thalamo-frontal psychosis (C) 124–125
Varo-Prieto, J. R. *see* **Martinez-Arevalo, M. J.** *et al* (SP) 679–681
Vaughan, K. *et al.* Eye-movement desensitisation. Symptom change in post-traumatic stress disorder 533–541
Verhoeff, N. P. L. G. *see* **Pilowsky, L. S.** *et al* 16–26
Verrill, Mark *see* **Robertson, Mary M.** *et al* (SP) 263–266
Vogler, George P. *see* **Newcomer, John W.** *et al* (SP) 834–838
Volkan, Vamik D. Identification with the therapist's functions and ego-building in the treatment of schizophrenia (suppl. 23) 77–82

Waddington, John L. and **Youssef, Hanafy A.** Evidence for a gender-specific decline in the rate of schizophrenia in rural Ireland over a 50-year period 171–176
Wahlberg, Karl-Erik *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26
Walker, Zuzana and **Seifert, Ruth**. Violent incidents in a psychiatric intensive care unit (SP) 826–828
Walsh, Catherine *see* **Crow, Timothy J.** *et al* 159–164
Walsh, Cathy *see* **Asherson, Philip** *et al* 619–624
Ware, C. J. *see* **Cowen, P. J.** *et al* 372–379
Warlow, Charles *see* **Sharpe, Michael** *et al* 380–386
Waterreus, A. *see* **Blanchard, M. R.** *et al* 396–402
Watts, D. *see* **Morgan, H. G.** (*Authors' reply*) (C) 698
Watts, Darryl and **Morgan, Gethin**. Malignant alienation (*Editorial*) 11–15
Waxman, David *see* **Rogers, T. D.** (*Current Literature*) 241–243
Wei, Jun *see* **Xu, Hai-Min** *et al* (SP) 251–253
Weich, Scott. Somatisation in general practice (C) 562
Weinberger, Daniel R. *see* **Hyde, Thomas M.** *et al* 494–500, 811–817
Weise, Charles *see* **Rickels, Karl** *et al* 802–805
Weissman, Myrna M. An attachment school of psychotherapy (C) 420–421
Weitzman, A. *see* **Fennig, S.** *et al* (SP) 839–841
Welburn, K. *see* **Ravindran, A. V.** *et al* 522–527
Wetzel, Martin W. *see* **Newcomer, John W.** *et al* (SP) 834–838
Whalley, Lawrence J. *see* **Geddes, John R.** *et al* (*Authors' reply*) (C) 564–565
Whalley, Lawrence J. *see* **Rodger, Colin R.** *et al* (SP) 106–109
Whitehead, Tony. Variations on the theme of euthanasia (C) 131
Wicki, Werner *see* **Merikangas, Kathleen Ries** *et al* 342–348
Wiese, M. *see* **Vaughan, K.** *et al* 533–541
Wiesel, Frits-Axel. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance (suppl. 23) 65–70
Wilhelm, Kay *see* **Parker, Gordon** *et al* 316–326
Wilkinson, Greg *see* **Piccinelli, Marco** (*Review Article*) 297–304
Wilkinson, Greg. The *British Journal of Psychiatry*: achieving excellence (*Editorial*) 1
Wilkinson, Simon R. Attachment theory (C) 129–130
Williams, C. J. *et al.* Sleep deprivation as a diagnostic instrument (SP) 554–556
Williams, F. *see* **Shamash, J.** *et al* (C) 849–850
Williams, Julie *see* **Asherson, Philip** *et al* 619–624
Williams, P. A. *see* **O'Flaithbheartaigh, S.** *et al* (SP) 684–686
Wilson, S. J. *see* **Lillywhite, A. R.** *et al* (SP) 551–554
Wilton, Lynda *see* **Edwards, J. Guy** *et al* 387–395
Wolfson, Paul *see* **Beer, Dominic** *et al* (C) 850
Wolkind, Stephen *see* **McGilchrist, Iain** *et al* (SP) 261–263
Wood, K. A. Nasal decongestant and psychiatric disturbance (C) 566–567
Wright, Pádraig and **Taylor, Mark**. Tardive dyskinesia as a risk factor for negative symptoms (C) 700–701
Wynne, Lyman C. *see* **Tienari, Pekka** *et al* (suppl. 23) 20–26

Xu, Hai-Min *et al.* Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia (SP) 251–253

Yates, P. *see* **Thalayasingam, S.** *et al* (C) 417–418
Yeomans, J. D. I. *see* **Williams, C. J.** *et al* (SP) 554–556
Youssef, Hanafy A. *see* **Waddington, John L.** 171–176

Zibin, Terry *see* **O'Croinin, Fergus** *et al* (C) 417

PART III. BOOK REVIEWS AND BJP REVIEW OF BOOKS NO. 7 (JANUARY 1994)

Abraham, S. and **Llewellyn-Jones, D.** Eating disorders – the facts (Dora Black) (R of B) 22–24
Ainscoff, Carolyn and **Toon, Kay**. Breaking free. Help for survivors of child sexual abuse (Jane Roberts) 860–861
Akhtar, Salman. Broken structures: severe personality disorders and their treatment (J. Stuart Whiteley) (R of B) 14–17

Baring, Anne and **Cashford, Jules**. The myth of the goddess: evolution of an image (Rosalind Ramsay) (R of B) 28–29
Barker, P. J. A self-help guide to managing depression (Dora Black) (R of B) 22–24
Baron-Cohen, Simon, Tager-Flusberg, Helen and **Cohen, Donald** (eds). Understanding other minds – perspectives from autism (Panos Vostanis) 425
Bazire, S. Psychotropic drug directory 1993 (E. Szabadi) 715–716
Bell, David S. Medico-legal assessment of head injury (Alice M. Parshall) 569
Brandell, Jerrold R. (ed.). Counter-transference in psychotherapy with children and adolescents (Peter Bruggen) 860
Breggin, Peter. Toxic psychiatry, drugs and electroconvulsive therapy: the truth and the better alternatives (Patricia R. Casey) 137
Brill, Norman Q. America's psychic malignancy: the problem of crime, substance abuse, poverty and welfare – identifying causes with possible remedies (Wilson Firth) (R of B) 1–3
Bugental, James F. T. The art of the psychotherapist: how to develop the skills that take psychotherapy beyond science (Andrew Clark) 279

Cassem, Ned H.(ed.). Handbook of general hospital psychiatry (3rd edn) (Michael Sharpe) 858–859
Chessick, Richard. What constitutes the patients in psychotherapy: alternative approaches to understanding (Terry Birchmore) 280–281, 571
Cook, Mark. Levels of personality (2nd edn) (David Winter) 859

de Silva, P. and **Rachman, S.** Obsessive compulsive disorder – the facts (Dora Black) (R of B) 22–24
Dryden, Windy. Reflections on counselling (Eric Button) 858
Dryden, Windy and **Hill, Larry K.** (eds). Innovations in rational-emotive therapy (Duncan Cramer) 137–138

Fava, M. and **Rosenbaum, J. F.** (eds). Research designs and methods in psychiatry (Peter Jones) (R of B) 6–9
Freeman, Chris and **Tyrer, Peter** (eds). Research methods in psychiatry. A beginner's guide (2nd edn) (Peter Jones) (R of B) 6–9

Galaburda, Albert M. Dyslexia and development – neurobiological aspects of extraordinary brains (Ken Barrett) 428
Gillberg, Christopher and **Coleman, Mary**. The biology of the autistic syndromes (2nd edn) (Lorna Wing) 138–139
Goei, Leonie de and **Vijselaar, Joost** (eds). Proceedings of the first European Congress on the History of Psychiatry and Mental Health Care (Hugh Freeman) 570
Gomez, Joan. Psychological and psychiatric problems in men (George J. Lodge) 278
Goodnick, P. and **Klimas, N.** (eds). Chronic fatigue and related immune deficiency syndromes (Simon Wessely) 276
Gram, L., Johannessen, S. I., Osterman, P. O. and **Sillanpää, M.** (eds). Pseudo-epileptic seizures (Michael R. Trimble) 282–283
Greenblatt, Milton. Anatomy of psychiatric administration. The organisation in health and disease (Bertram Mandelbrote) (R of B) 3–5
Gregoire, Alain and **Pryor, John P.** (eds). Impotence – an integrated approach to clinical practice (Dennis Friedman) (R of B) 12–14
Grof, P., Akhter, M. I., Campbell, M., Gottfries, G. G., Khan, I., Lapierre, Y., Lemberger, L., Muller-Oerlingshausen, B. and **Woggon, B.** Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines (John C. Cookson) 429

Hill, Michael. The Welfare State in Britain: a political history since 1945 (Hugh Freeman) 136–137
Hindmarch, Ian and **Stonier, Peter** (eds). Human psychopharmacology: measures and methods (Vol. 4) (David Healy) 428–429
Hollins, Sheila and **Hutchinson, Deborah**. A new home in the community (M. Bambrick) 717
Hollins, Sheila and **Sinason, Valerie**. Bob tells all (M. Bambrick) 717
Holmes, Jeremy. Between art and science (Chris Maloney) (R of B) 9–11
Hsu, L. K. George and **Hersen, Michael** (eds). Research in psychiatry. Issues, strategies and methods (Peter Jones) (R of B) 6–9

Johnson, Bankole A. Solving conundrums in clinical psychiatry: a guide to viva voce examinations (Paula McKay) 861

Kernberg, Otto F. Aggression in personality disorders and perversions (J. Stuart Whiteley) (R of B) 14–17
Kline, Paul. Personality: the psychometric view (John Pilgrim) 861
Kohut, Thomas A. Wilhelm II and the Germans: a study in leadership (Hugh Freeman) (R of B) 25–27

Lader, Malcolm, Edwards, Griffith and **Drummond, Colin** (eds). The nature of alcohol and drug related problems (Brian D. Hore) 427
La Fond, John Q. and **Durham, Mary L.** Back to the asylum: the future of mental health, law and policy in the United States (Bertram Mandelbrote) (R of B) 3–5
Langs, Robert. Science, systems and psychoanalysis (Chris Maloney) (R of B) 9–11
Lecca, Pedro J. and **Watts, Thomas D.** Preschoolers and substance abuse (Judith Nicholls) 568
Lewin, R. A. and **Schulz, C.** (eds). Losing and diffusing – borderline transitional object and self-relations (Richard Carvalho) 714
Liebling, Alison. Suicides in prison (N. M. J. Kennedy) 857

MacGregor, John. The discovery of the art of the insane (Digby Quested) (R of B) 19–22
Meloy, J. Reid. Violent attachments (T. Maden) 138
Melville, J. and **Subotsky, F.** Does my child need help? (Dora Black) (R of B) 22–24
Moffitt, Alan, Kramer, Milton and **Hoffmann, Robert** (eds). The functions of dreaming (D. F. Scott) 135
Montgomery, Stuart (ed.). Psychopharmacology of panic (Malcolm Lader) 570–571

Nelson, Thorana S. and **Trepper, Terry S.** (eds). 101 interventions in family therapy (Jenny Altschuler) 281

O'Hagan, Kieran. Emotional and psychological abuse of children (Bernadette Wren) 277–278
O'Shea, B. and **Falvey, J.** A textbook of psychological medicine (Tom Fahy) 429

Parkes, C. M., Stevenson-Hinde, J. and **Marris, P.** (eds). Attachment across the life cycle (Antony D. Cox) 135–136
Parkin, Alan J. and **Leng, Nicholas R. G.** Neuropsychology of the amnesic syndrome (Angela Costello) 716–717
Paykel, Eugene S. (ed.). Handbook of affective disorders (2nd edn) (Hugh Freeman) 573
Perlman, Daniel and **Jones, Warren H.** (eds). Advances in personal relationships (Vol. 4) (Graham Ash) 280
Pernanen, Kai. Alcohol in human violence (E. Jane Marshall) 856–857
Phillips, Adam. On kissing, tickling and being bored (Stephen Gladwell) 278–279
Pines, Dinora. A woman's unconscious use of her body: a psychoanalytical perspective (Margaret R. Malcolm) 572
Pollock, G. H. (ed.). How psychiatrists look at ageing (Joyce H. Pickett) 277

Rogers, Ann, Pilgrim, David and **Lacey, Ron**. Experiencing psychiatry: users' views of services (Susan F. Mitchell) 569–570
Rose, Philip (ed.). Social trends 23 (Louis Appleby) (R of B) 17–19
Royal College of Physicians. Smoking and the young (Dora Black) (R of B) 22–24
Rutter, Michael and **Rutter, Marjorie**. Developing minds: challenge and continuity across the life span (Hugh Barnes) 139

Saitoh, Satoru, Steinglass, Peter and **Schuckit, Marc A.** (eds). Alcoholism and the family (Mary Alison Durand) 856
Sandler, Joseph, Dare, Christopher and **Holder, Alex**. The patient and the analyst (2nd edn) (Rachel Leheup) 424–425
Scambler, A. and **Scambler, G.** Menstrual disorders (Dora Black) (R of B) 22–24
Schneider, Carl D. Shame, exposure and privacy (Terri Eynon) 278
Schou, Mogens, Lithium treatment of manic-depressive illness: a practical guide (5th edn) (Stephen Curran) 279–280
Scull, Andrew. The most solitary of afflictions. Madness and society in Britain, 1700–1900 (Henry R. Rollin) 714–715
Segal, Julia. Melanie Klein: key figures in counselling and psychotherapy (Stephen Wilson) 713
Segal, Julia and **Simkins, John**. My mum needs me – helping children with ill or disabled parents (Beverley Norton) 283
Severy, Lawrence J. (ed.). Advances in population: psychosocial perspectives (Gaius Davies) 136
Siegel, Judith. Repairing intimacy – an object relations approach to couples therapy (Sasha Brookes) 859
Sinclair, N. Duncan. Horrific traumata: a pastoral response to the post-traumatic stress disorder (L. Stephen O'Brien) 571–572
Solomon, Irving. The encyclopaedia of evolving techniques in dynamic psychotherapy: the movement of multiple models (Teresa Black) 281–282
Stewart, William. An A–Z of counselling theory and practice (Nigel Beail) 713
Stimmel, B. The facts about drug use (Dora Black) (R of B) 22–24
Strean, Herbert S. Resolving counter-resistances in psychotherapy (Dorothy Oglethorpe) 426–427
Szasz, Thomas. A lexicon of lunacy: metaphoric malady, moral responsibility, and psychiatry (Wilson Firth) (R of B) 1–3

Talbot, John A., Hales, Robert E. and **Keill, Stuart L.** (eds). Textbook of administrative psychiatry (Bertram Mandelbrote) (R of B) 3–5
Trinble, Joseph E., Bolek, Catherine S. and **Neimcryk, Steve J.** (eds). Ethnic and multicultural drug abuse: perspectives on current research (Tom Fahy) 428
Tyrer, Peter, Higgs, Roger and **Strathdee, Geraldine**. Mental health and primary care. A changing agenda (Tom Fahy) 424
Tyrer, Peter and **Stein, George** (eds). Personality disorder reviewed (J. Stuart Whiteley) (R of B) 14–17

Ussher, Jane and **Baker, Christine D.** (eds). Psychological perspectives and sexual problems (Waguih R. Guirguis) 857–858

van Praag, Herman. "Make believes" in psychiatry or the perils of progress (Wilson Firth) (R of B) 1–3
Varma, Ved (ed.). How and why children fail (Howard Roberts) 569

Wagner, Gorm and **Kaplan, Helen Singer**. The new injection treatment for impotence – medical and psychological aspects (Dennis Friedman) (R of B) 12–14
Walker, Moira. Surviving secrets (Marian Perkins) 282
Weisberg, Leon A. Neurology for the psychiatry speciality board review (Ian P. Everall) 572–573
Weisz, John R. and **Weiss, Bahr**. Effects of psychotherapy with children and adolescents (Rachel Leheup) 426
West, Donald J. and **de Villiers, Buz**. Male prostitution (Michael King) 425–426
Whitaker, Leighton C. and **Slimak, Richard E.** (eds). College student development (Chris Lucas) 568
White, Tony. Management for clinicians: a handbook for doctors and nurses (Dougal Mackay) 276–277
Whitehouse, Peter J. (ed.). Dementia (J. P. Wattis) 716
WHO Regional Office for Europe. AIDS among drug users in Europe: second review (J. S. Madden) 713–714

Printed in Great Britain by Henry Ling Ltd., at the Dorset Press, Dorchester, Dorset